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This thesis is divided into five chapters. The overarching working hypothesis is published as a 
‘perspective’ article in International Journal of Biochemistry and Cell biology, 2017 
https://doi.org/10.1016/j.biocel.2017.01.011 and is also discussed in the last section of 
Chapter - 1. Hence, there are similarities in the published article and sections of Chapter - 1. 
The working hypothesis states that endogenous PLA2 near docking/ fusion sites provide basal 
levels of LPC that acts as a ‘molecular brake’ against spontaneous fusion, and FFA that aids in 
trans-SNARE complex formation to ensure efficient docking of secretory vesicles to the 
plasma membrane (PM) prior to triggering. The data in Chapters - 2 and - 3 then test the 
working hypothesis and are also published as original articles in cells, 2019 
https://doi.org/10.3390/cells8040303 and Biochemical and Biophysical Research 
Communications, 2019 https://doi.org/10.1016/j.bbrc.2019.05.106, respectively. The data 
presented in Chapter - 2, indicate that vesicle-associated endogenous PLA2 isozymes – sPLA2 
in the CV lumen and iPLA2 on the CV surface – maintain docking/priming steps in regulated 
exocytosis. The specific CV localization of sPLA2 and iPLA2 is also shown, using highly 
sensitive two-dimensional gel electrophoresis (2DE) immuno-blotting with selective 
antibodies on separated luminal and membrane fractions. Biochemical assays confirmed that 
these isozymes are catalytically active; sPLA2 showed higher efficiency in catalyzing PE than 
PC, while iPLA2 showed no such preference. Notably, a significant increase in the de novo 
metabolite TAG upon iPLA2 inhibition confirmed the role of this isozyme in maintaining 
membrane lipid homeostasis. Removal of CV surface proteins by treatment with trypsin, 
coupled with the use of a selective PLA2 substrate (PED6) also confirmed the presence of an 
active PLA2 isozyme in the outer CV membrane. Overall, the data presented in Chapter - 2, 
provide evidence in support of the working hypothesis. To test the hypothesis further, in 





canonical PLA2 metabolites, are shown to impair docking/priming and actual membrane 
merger steps, respectively. The observed decrease in docking/priming induced by exogenous 
ARA is contradictory to part of the working hypothesis that was put forth based on existing 
literature. That exogenous LPC and ARA were to a significant extent converted into 
endogenous PC and FFA, respectively, indicated that endogenous enzymes maintain lipid 
homeostasis in the native vesicle membrane. With the intension of activating CV luminal 
sPLA2, Phospholipase A2 activating peptide (PLAP) - a melittin homolog, was used in Chapter 
– 4. The data presented indicates that PLAP inhibited CSC, and CV fusion by impairing 
docking/priming and also altered endogenous PE and FFA levels in the CV membrane. This 
suggests that PLAP caused no change in the CV luminal sPLA2 activity; an observation 
contrary to the earlier in vitro studies. To test further, PLAP was delivered to mouse chromaffin 
cells and was seen to reduce membrane capacitance and readily releasable pool (RRP) size, 
when triggered with depolarizing pulses. This substantiate that the PLAP blocked a common 
underlying mechanism associated with the late stages of Ca2+ triggered exocytosis. The 
Chapter - 4 is another manuscript in preparation and will be submitted to an appropriate 
journal. Finally, in Chapter - 5, the Discussion and Future Directions, all key finding in this 
thesis are reviewed and integrated with a critical evaluation of the existing literature, and 
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In the late 1950s during the investigation of secretory processes in the pancreatic cell, secretory 
vesicles were observed near the plasma membrane (PM), apparently in preparation to release 
their content [3]. As we understand today, this was amongst the last steps of regulated 
exocytosis (also see below), that prepares vesicles to release their content into the extracellular 
space. In eukaryotes, the cell undergoes constitutive exocytosis (e.g., the fusion of vesicles 
budding off from trans-Golgi network to the PM) without apparent stimulation as a well-
defined trigger is yet unknown, as well as regulated exocytosis, which is usually triggered by 
an elevation of the intracellular calcium concentration ([Ca2+]free). Regulated exocytosis 
proceeds through multiple steps including (i) biogenesis and release of vesicles from the trans-
Golgi network; (ii) their translocation to the PM; (iii) initial contact and ‘tethering’ with the 
PM [4]; (iv) stabilised contact or ‘docking’ on the PM; (iv) ATP-dependent and independent 
priming reactions to become release-ready [5,6] - notably, there would seem to be priming 
reactions that occur both before and after docking [4,7-9]. Therefore, before triggering, vesicles 
remain in close apposition (~3-8 nm, predicted by course-grain model [10] and [11]), with the 
PM and; (v) upon elevation in [Ca2+]free, fully primed vesicles fuse with the PM, releasing 
membrane impermeable cargo stored in the vesicle lumen into the extracellular space (Figure 
- 1). Interestingly, the late steps, i.e., Ca2+ sensing, docking, priming, and actual membrane 
merger, appear to be highly conserved across all cell types [1,12-20]. Therefore, to better define 
these steps, the (lipidic or proteinic) components that carry out these functions are described as 
belonging to the fundamental fusion mechanism (FFM) and/or the physiological fusion 
machine (PFM)[1,21-23]. The components associated with FFM constitute the minimum 
essential machinery that induces the actual membrane merger steps and; PFM defines the 
efficiency of membrane merger, via ‘accessory’ components that regulate mechanisms such as 
Ca2+ sensing, docking, priming, and perhaps even fusion pore.  
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1. Rationale: CV isolated from unfertilized sea urchin eggs are an excellent model for 
studying the late steps of regulated exocytosis 
Sea urchins belong to the class Echinoidea, that diverged in the phylogenetic tree before the 
two whole-genome duplication events that occurred in the Chordate lineage [24]. Notably, 
Echinoidea is closer to the phylum Chordata to which all vertebrates belong, relative to other 
phyla.  Furthermore, the size of the urchin genome is about one-quarter that of the human 
genome (i.e., 814 megabase pairs (Mbp), relative to 3100 Mbp) [25-27]. Despite this, urchins 
possess genes representing all vertebrate gene families, including humans [27]. Therefore, in 
many instances, the urchin genome carries a single ‘original’ copy of the later vertebrate genes, 
hence proteins to regulate all fundamental processes, including fertilization. The fertilization 
of a sea urchin eggs occur externally, with the assistance of chemoattractants (e.g., peptides 
and cyclic nucleotides) that escort movement of sperms toward unfertilized eggs [28]. Upon 
fertilization, a transient, ‘fast block’ to polyspermy occurs in a fertilized egg, that changes the 
membrane potential from -70 mV to + 20 mV within 1-3 secs [29]; the positive membrane 
potential does not favor subsequent sperm attachment [29]. Then, to cause a permanent or ‘slow 
block’ to polyspermy, another mechanism initiates in ~20 s after sperm attachment and usually 
completes within ~1 min. This occurs due to increase in subplasmalemmal [Ca2+]free from ~0.1 
to 1 mM at the sperm attachment site, that triggers fusion of ~15,000 fully docked cortical 
secretory vesicles (CV) to the PM. Thus, releasing the luminal cargo into the extracellular space 
between the PM and vitelline layer. Released proteases cleave proteins that bind the vitelline 
layer to the PM and mucopolysaccharides induce an osmotic gradient causing movement of 
water into the space between PM and the vitelline layer. This expands the vitelline layer 
forming the fertilization envelope [30-32].  
Interestingly, CV remain fully prime, retain the ability to dock, sense increase in [Ca2+] 
and undergo homotypic as well as heterotypic fusion (e.g., CV-PM) even after isolation from 
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the eggs. The steps mentioned above are essentially the late steps of regulated exocytosis and 
are described by a characteristic sigmoidal Ca2+ activity curve [33-39]. That, increase in 
[Ca2+]free triggers fusion of the secretory vesicles to the PM is consistent across cell types 
[20,38-42], indicating a conserved underlying mechanism that drives membrane merger (and 
the steps immediate preceding it). Hence, information learned about the late steps of regulated 
exocytosis using CV-CV, or CV-PM fusion has proven to be consistent across other secretory 
model systems [16,43]. To better understand FFM, the fusion of secretory vesicles to the PM 
was suggested to be triggered by a hypothetical entity or activatable fusion complexes, which 
were estimated to be randomly distributed on a CV with an average of 5-9 such complexes per 
CV. Nevertheless, molecular components of the active fusion complex remain unknown,  
activation of a single fusion complex appeared sufficient for triggering the membrane merger 
[35,44-46]. Importantly, the mechanisms that precede membrane merger also seem to require 
calcium sensors operating at basal i[Ca2+]free. Indeed, studies have also suggested that docking 
and priming occur at different [Ca2+]free, with docking potentially occurring at lower nanomolar 
(nM) levels than priming [47-49] and membrane merger require increased Ca2+ levels 
[38,40,45]. Therefore, local changes in [Ca2+]free near fusion and docking sites even before 
triggering is crucial for several underlying processes, such as docking and priming.  
There are several advantages associated with studying the late steps of regulated 
exocytosis using CV-CV and CV-PM fusion; foremost is that a single gravid female urchin 
releases gram quantities of eggs, and each carries ~15,000 stage-specific, release-ready CV. 
Thus, such high egg yields enable a variety of straightforward manipulations (ex-vivo 
treatments) that are impossible with isolated mammalian secretory vesicles that de-prime 
during isolation. Additionally, endogenously docked CV on PM fragments (e.g., cell surface 
complexes (CSC) which are essentially cell ghosts) remain stably docked even hours after 
isolation [18] or can be detachment from the PM to isolate high purity CV. Thus, homotypic 
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CV or heterotypic CV-PM fusion enabled highly focussed investigations to dissect molecular 
mechanisms associated with the late steps of regulated exocytosis. Critically, this also enables 
tight coupling of the functional assays (standard and settle fusion assays) with parallel 
molecular analyses to directly relate specific molecules with the underlying mechanism(s) 
[22,23,37,44,50]. The CV-CV fusion using the standard fusion assay measures the fundamental 
ability of CV to fuse while the settle fusion assay assesses the capacity of the endogenous 
machinery to support docking/priming [23,37]. Studies using homotypic CV fusion also reduce 
the large ‘molecular background’ imposed by components in the PM. Thus providing better 
focus to identify endogenous components in the native membrane that play direct roles in the 
late steps of regulated exocytosis [44,51,52].  
2. Lipid classes and their effect on native membrane fusion 
Major lipidic components of the native membrane include, cholesterol (CHOL), sphingomyelin 
(SM), phosphatidyl-choline, -inositol, -ethanolamine, -serine (PC/PI/PE/PS) and phosphatidic 
acid (PA) [53-56]. These lipids are asymmetrically distributed in the inner and outer membrane 
monolayers, and their levels are tightly regulated enzymatically [2,57-64]. The distribution of 
PE, PS, PI dominates in the cytoplasmic monolayer, and PC and CHOL are approximately 
equally distributed in both monolayers [63,65,66]. Unfertilized sea urchin eggs contain ~54% 
triglycerides, ~33% phospholipids, and ~9% cholesterol [67]; in terms of per 100 μg protein, 
PE, PI, PC and cholesterol levels are 86.0 nmol, 61.0 nmol, 25.3 nmol, and 16.2 nmol, 
respectively while PS, SM, PA are < 2.5 nmol [56]. However, in isolated CV, PE, PI, PC, PS, 
SM and CHOL constitute 10.2%, 5.1%, 36.9 %, 5.9%, <0.4%  and 23.6%, respectively and; of 
all lipids ~15% are anionic under physiological conditions [68]. PS and PA fall under the 
category of anionic lipids as attain a deprotonated negative charge and bind to di- and trivalent 
cations, such as Ca2+ [69-71]. Perhaps, due to this Ca2+ binding capacity, PS can sense Ca2+ at 
the triggering steps [22]. While PA can also bind to Ca2+, no change in Ca2+ sensitivity occurred 
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due to the incorporation of PA into the CV membrane [36]. Instead, PLD-derived endogenous 
PA was seen to mediate docking/ priming [23,72].  
The incorporated lipids in the membrane either lowers or increases the energy required 
to bend, rearrange, and merge the membrane bilayers [15,16,55,73-75], due to their 
spontaneous curvature. Lipids, such as lysophosphatidylcholine (LPC), have a large polar head 
group and relatively ‘slim’ hydrocarbon tail. Such lipids are defined as having positive 
spontaneous curvature. While arachidonic acid (ARA) and CHOL carry a small head group 
and proportionally ‘bulkier’ tails. These lipids are defined as having spontaneous negative 
curvature [1,74]. According to the Stalk-pore hypothesis, membrane merger proceeds through 
transient steps, that include (i) merging of the proximal monolayers (i.e., merging of the outer 
vesicle monolayer with the inner PM monolayer, in case of heterotypic fusion and; outer 
monolayers of contacting vesicles, in case of homotypic fusion). This follows (ii) merging of 
the distal monolayers (i.e., merging of the inner vesicle monolayer with the outer PM 
monolayer, in case of heterotypic fusion and; inner monolayers of contacting vesicles, in case 
of homotypic fusion) [15,16,55,74]. The entire fusion process proceeds from the point of 
contact between merging bilayers, followed by the formation of a stalk and hemifusion 
diaphragm (HD), and then to formation, opening, and expansion of a fusion pore (Figure - 2). 
Notably, merging of proximal monolayers is promoted on introducing negative curvature lipids 
to these monolayers; this supports stalk formation. However, merging of these monolayers is 
inhibited on introducing positive curvature lipids [2,55]. In contrast, merging of distal 
monolayers is promoted and inhibited, respectively, upon introducing positive and negative 
curvature lipids [2,55], thus directly affecting the formation, opening, and expansion of the 
fusion pore. Hence, upon Ca2+ triggering, membrane merger proceeds through high curvature 
lipid intermediates at exocytotic sites that are likely to be localized in CHOL and sphingolipid 
(SL) microdomains [1,76]. In addition to maintaining the integrity of exocytotic sites, CHOL 
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also facilitates membrane merger by lowering the energy barrier for the initial fusion step 
[1,34], and SL regulate the efficiency of the native Ca2+ triggered membrane fusion mechanism, 
presumably by localizing and maintaining other critical components to enable rapid response 
upon triggering [37,50].  
3. Phospholipase A2 isozymes and their suggested roles  
Mammalian phospholipase A2 (PLA2) belong to a diverse enzyme family, that is sub-divided 
into 15 Groups (IXV) [77-80]; nevertheless, all hydrolyze membrane phospholipids at the sn-
2 position producing lysophospholipids (LPL) and free fatty acids (FFA) (Figure - 3). 
However, a broader classification, based on their subcellular localization and Ca2+ requirement, 
categorizes these into (i) Ca2+-dependent secretory or sPLA2; (ii) Ca2+-dependent cytoplasmic 
or cPLA2 and; (iii) Ca2+ independent cytoplasmic or iPLA2 (also see Chapter - 2 and [81]).  
sPLA2 are 12-19 kDa secretory proteins that have 5-7 conserved disulfide bonds that 
contribute to their high stability. Once secreted, their Ca2+ requirement for catalysis is in the low 
millimolar (mM) range with no strict fatty acid selectivity, although most target PE, PG, PI, and 
PS [78,82]. In contrast, cPLA2 isozymes have a molecular weight ranging from 61-114 kDa 
[78,80] and are generally found in the cytosol. These enzymes require micromolar (μM) Ca2+ 
for membrane binding, via conserved lipase consensus sequences - GXSXG, GXSGS or 
GXSXV in the C2 domain at the N-terminal [77,78,83]. Mammalian cPLA2 has six isoforms, 
designated as α, β, γ, δ, ε, ζ, of them, only α and β have N terminal C2 domain [77,78,83]. 
Similarly, iPLA2 are intracellular enzymes that do not require Ca2+ beyond basal cytosolic 
levels for activity and carry a GXSXG lipase and GXGXXG nucleotide consensus sequences. 
Mammalian iPLA2 has six isoforms, designated as β, γ, δ, ε, ζ, and η and their molecular 
weights range from 27 to 146 kDa [2,84,85]. (Note: sequence alignment with percent identity 
and similarity between characterized human, murine and putative PLA2 isozymes is shown 
Chapter - 2 and [81]). While secreted sPLA2 is associated with inflammation, as these clear 
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variety of non-cellular targets (e.g., virus, bacteria, exosomes, etc.) by cleaving the membrane 
phospholipids from outside of the cell [86]. A well-established function of iPLA2β is membrane 
phospholipid remodelling via the Lands cycle [2,84,85]. At steady state, the molecular species 
composition in the membrane is regulated by de novo biosynthesis (or the Kennedy cycle) 
[58,87] and acyl chain remodelling (or the Lands cycle) [57] (Figure - 4), the latter mediated 
by phospholipases and acyltransferases or transacylases [61,88-91]. The levels of 
phospholipids are thus maintained via Lands cycle due to the basal activities of enzymes, 
including iPLA2 that metabolize membrane phospholipids to generate lysophospholipids, and 
a FFA is also liberated.  Released FFA rapidly converts to fatty acyl-CoA and incorporate back 
into the membrane phospholipids via de novo pathway [2,88,89] (also see Chapter - 3).  
1.4 SNAREs, PLA2, and native membrane merger    
The Clostridium botulinum (BotX) and Clostridium tetani (TetX) toxins were early tools to 
study neurotransmission, which cleaved synaptosome-associated protein-25 (SNAP-25), 
vesicle-associated membrane protein-2 (VAMP-2), and single-pass transmembrane proteins 
(syntaxin) and also blocked regulated secretion [92-94]. VAMP-2 and syntaxin carry a trans 
membrane-domains (TMD) that associate with membrane [95,96] while the association of 
SNAP-25 to the membrane occurs via its palmitoylated residues [97]. All these proteins also 
carry a cytoplasmic domain that interacts to form stable SDS-resistant heterotrimeric trans or 
cis SNARE complexes; docking and priming are believed to be the functional consequence of 
trans SNARE complex formation. As toxins cleaved SNAP-25, VAMP-2, and syntaxin 
(collectively termed as SNAREs) and caused a parallel block in regulated secretion, an 
oversimplified interpretation led to the suggestion that perhaps SNAREs also catalyze actual 
membrane merger, in addition to mediating the upstream docking and priming steps. Therefore, 
to understand the underlying mechanism, the original SNARE hypothesis suggested that N-
ethylmaleimide-sensitive factor (NFS), an ATPase, disrupt trans SNARE complexes that drive 
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membrane merger [98]; nevertheless, it has also been long known that actual membrane merger 
is independent of ATP [5,46,99,100]. Therefore, the ‘modified’ SNAREpin hypothesis 
suggested that NSF disassembles cis SNARE complexes, after fusion, to recover monomeric 
SNAREs for further rounds of fusion [13]. Thus emphasizing that SNARE assembly play a 
central role in membrane merger. According to the SNAREpin hypothesis, membrane merger 
is driven by the NH2 terminus-to-COOH terminus ‘zippering’ of the parallel coiled-coil 
SNARE domains, that pulls two apposed membranes together [101], also purportedly 
providing sufficient free energy to overcome inter-membrane repulsive forces [102]. However, 
SNARE-driven membrane merger still fails to explain homotypic and heterotypic CV fusion 
[33,35,103] and homotypic yeast vacuole fusion [104]. These studies instead suggested the role 
of SNAREs in targeting, docking, and priming [33,35,81,103] (also see Chapter - 3 and 
Discussion and future direction).  
On average, a CV contains ~5500, ~700, and ~300 copies of VAMP, SNAP-25, and 
syntaxin, respectively [33,35,103]. All these proteins carry a substantial number of trypsin, 
chymotrypsin, papain, and clostripain cleavage sites in their cytoplasmic domains that interact 
to form trans SNARE complexes [35]. Notably, Ca2+-triggered CV fusion occurred despite the 
proteolytic removal of the SNAREs using trypsin, papain, and clostripain [35]. In contrast, 
fusion reduced significantly in CV that were treated with chymotrypsin without substantial 
removal of the SNAREs [105]. Also, CV lost their fusion competence when treated with 
chaotropic buffer, without affecting Ca2+ induced disruption of SNARE complexes [44]. 
Furthermore, disruption of SNARE complexes using saturating levels of Ca2+ (i.e., > 100 µM) 
triggered homotypic CV fusion [33], while triggering with Sr2+ and Ba2+ did not disrupted 
SNARE complexes, but triggered homotypic CV fusion [44]. Therefore, based on these studies, 
the actual membrane merger step appears to be independent of inter-membrane SNARE 
complex formation.  
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Notably, BotX decreased ARA levels in addition to blocking acetylcholine release 
[106], suggesting possible action against PLA2, in addition, to SNAP 25 cleavage [107]; 
nevertheless, this has never been shown or perhaps explored (also see [108] for other potential 
targets of BotX). Also, based on in vitro studies, exogenous ARA is thought to enhance 
SNARE complex formation by releasing syntaxin from syntaxin/Munc18 complexes [109,110] 
and also suggested to restrict the lateral motion of secretory vesicles that are closer to the PM 
[111]. However, whether ARA acted as ‘active’ species is unknown, as supplemented ARA 
can also convert to other FFA species (see Chapter - 3 and [112]). Overall, the current 
interpretation in the field is that PLA2 or its metabolites may directly or indirectly promote 
SNARE complex formation, hence promoting regulated exocytosis.  
In this thesis, the role of PLA2 in the late steps of regulated exocytosis is thus 
investigated. Firstly, a working hypothesis was proposed [2], based on already existing 
information relating to the spontaneous curvature of the canonical PLA2 metabolites, LPC and 
ARA [16,55,73-75], their effects on SNARE complex formation in vitro [110,113,114] and 
membrane merger steps [16,55,73,74]. The working hypothesis stated that the localized 
endogenous PLA2 supply basal level of LPL and FFA near fusion sites to maintain 
docking/priming steps; LPC acts as molecular fusion ‘brake’ to block membrane merger before 
Ca2+ triggering while ARA promotes SNARE complexes formation, thus supporting 
docking/priming steps (Figure - 5). Notably, estimated levels of LPC and ARA on the PM and 
vesicle membrane in an unstimulated state appear to be extremely low [2,115] and both these 
metabolites can also rapidly metabolize [2] (also see Chapter - 3 and [112]). Therefore, if 
ARA would have to support trans SNARE complex in vivo, a localized PLA2 near docking or 
fusion sites in the PM or associated with vesicle would be needed to generate sufficient levels 
of ARA to carry out such roles. This has been depicted in the working hypothesis [2]. Using 
targeted omics, the vesicle-associated PLA2 isozymes – CV luminal sPLA2, and surface iPLA2 
11 
 
– were identified and characterized [81] and were seen to regulate docking/priming steps of 
regulated exocytosis (Chapter - 2) and [81]. This substantiated the working hypothesis. To 
confirm, canonical PLA2 metabolites, LPC and ARA were supplemented to CV suspension, 
and treatment effects confirmed that LPC acted as molecular fusion ‘clamp’ (Chapter - 3). 
However, in contrast, to the suggested role in the working hypothesis, ARA impaired 
docking/priming. On further attempts to manipulate CV luminal sPLA2 using phospholipase 
A2 activating peptide (PLAP) suggested that docking/priming steps, the endogenous lipid 
composition and SNARE complex formation or ‘zippering’ could be inter-related. (Chapter - 
4). Importantly, PLAP also reduced membrane capacitance and readily releasable pool (RRP) 
size in the chromaffin cells, thus highlighting the similarity in the molecular state of RRP 
































Figure 2. Stalk-pore hypothesis: membrane fusion proceeds from point of contact through to 






Figure 3. Hydrolytic site of phospholipases A2 on a glycerol 
phospholipid. PLA2 enzymes cleave at sn-2 positions to generate 














Figure 4. Membrane remodelling via Kennedy and Lands cycles: In the Kennedy pathway, 
FFA is progressively converted to finally yield PE, PC, PS, and PI. In contrast, in Lands cycle, 
existing PE, PC, PS, and PI are metabolized by PLA2, resulting in the formation of LPL and 
FFA. The released FFA is converted either to eicosanoids or into fatty acyl-CoA; the LPL is 






















Figure 5. a. Non-contacting membranes; b. membranes in close proximity. Working 
hypothesis: a fusion ready state is maintained by localized PLA2 that produces LPL and ARA; 
LPL acts as a local ‘fusion block’ inhibiting the premature (i.e. pre-stimulus) merger of the 
proximal membranes while ARA supports the trans SNARE complex(es) in maintaining the 
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a  b  s  t  r  a  c  t
Membrane  fusion  is  a fundamental  molecular  mechanism  by  which  two  apposed  membrane  bilayers
coalesce  in  rapid,  transient  steps  that  enable  the  successive  merging  of the  outer  and  inner  leaflets  allow-
ing lipid  intermixing  and  subsequent  mixing  of  the  two  previously  separate  compartments.  The actual
membrane  merger  mechanism  – fusion,  by  definition  – is conceptualized  to  be  protein-  or  lipid-centric.





lipid  intermediates.  By  cleaving  membrane  phospholipids  at the  sn-2  position,  Phospholipase  A2 gener-
ates  metabolites  that  exert  spontaneous  curvature  stress  (both  negative  and  positive)  on  the  membrane,
thus influencing  local  membrane  bending  by  altering  the  packing  and  conformation  of  lipids  and  pro-
teins,  respectively.  Such  changes  could  potentially  modulate  priming  and  attachment/docking  steps  that
precede  fusion,  as well  as  the  membrane  merger  steps  per  se.
©  2017  Elsevier  Ltd. All  rights  reserved.. Native membrane organization
The basic framework of native membranes is best described
y the Fluid Mosaic Model: lipidic constituents of the membrane
orm bilayers in which polar head groups point outward and the
cyl tails face each other to minimize contact with the aqueous
edium (Singer and Nicolson, 1972). Membrane proteins associate
ith the hydrophilic polar head groups (peripheral proteins) and/or
ith the hydrophobic acyl-glycerol regions (integral proteins). The
roteins and lipids in the membrane are in constant rotational
nd lateral motion, and lipids also move between the monolay-
rs (i.e. trans-bilayer) via flip-, flop- and scramblases, contributing
o the lipid asymmetry in the membrane leaflets (Contreras et al.,
010). Updates to the model include the presence of transient
on-lamellar lipid phases, lipid rafts and inconsistent mem-
rane thickness, and extreme protein overcrowding (Engelman,
005). Nonetheless, cholesterol, sphingomyelin, phosphatidyl-
holine (PC), phosphatidylinositol (PI), phosphatidylethanolamine
PE), phosphatidylserine (PS), plasmalogen and phosphatidic acid
Abbreviation: ARA, arachidonic acid; DAG, diacylglycerol; FFA, free fatty acid;
D, hemifusion diaphragm; HII, inverted hexagonal; IM,  inverted micellar; L, Lamel-
ar; LPC, LPS, LPE, lysophosphatidyl-choline, -serine, - ethanolamine; PC, PS, PE,
hosphatidyl - choline, - serine, - ethanolamine; PA, phosphatidic acid; PUFA,
olyunsaturated free fatty acid; [Ca2+]i, intracellular calcium concentration.
∗ Corresponding author.
E-mail address: jcoorssen@brocku.ca (J.R. Coorssen).
ttp://dx.doi.org/10.1016/j.biocel.2017.01.011
357-2725/© 2017 Elsevier Ltd. All rights reserved.(PA) are the core structural components of the membrane. PE, PS,
and PI dominate in the cytoplasmic leaflet, whereas PC and choles-
terol are relatively equally distributed between leaflets.
Lipids have intrinsic curvatures or conformations depending
on the relative size of their polar head group to the acyl-
glycerol region. The packing of similar lipids in the membrane
thus exerts spontaneous local curvature stress (negative or pos-
itive) that influences local membrane bending; for example,
lyso-phosphatidylcholine (LPC) with a large polar head group and
proportionally ‘slimmer’ acyl-glycerol region, is defined as having
positive spontaneous curvature (Fuller and Rand, 2001). Therefore,
when introduced into one monolayer, LPC tends to curve the mono-
layer in the direction of the polar head groups. Conversely, sterols
such as cholesterol, and free fatty acid (FFA) species such as arachi-
donic acid (ARA), have a small head group and proportionally larger
hydrocarbon region; this is defined as negative spontaneous cur-
vature, as the presence of such species curves the monolayer in
the direction of the hydrocarbon chains. Membrane bending is fur-
ther complicated by acyl chain length and degree of unsaturation.
For instance, induction of the high curvature inverted hexagonal
(HII) phase by diacylglycerol depends on the degree of unsatura-
tion of the surrounding PC (Szule et al., 2002) or upon the presence
of cholesterol (Coorssen and Rand, 1990). In order to understand
potential effects on native membranes, it is thus critical to note
that lipid assemblies can adopt a number of phases in excess aque-
ous medium in vitro (Fig. 1). These include (i) Lamellar (L) in
which lipids (e.g. phospho- and glycolipids) adopt a bilayer con-
2 D. Dabral, J.R. Coorssen / The International Journal of Biochemistry & Cell Biology 85 (2017) 1–5








































Fig. 2. Membrane remodeling via Kennedy and Lands cycles: In the Kennedy path-
way, FFA is progressively converted to finally yield PE, PC, PS, and PI. In contrast,
in  Lands cycle, existing PE, PC, PS, and PI are metabolized by PLA2, resulting in thear  and (ii) inverted micellar (LPL and gangliosides); c. (i) Hexagonal and (ii) inverted
exagonal (PE and CL); d. (i) Cubic and (ii) inverted cubic (MAG) phases. (Adapted
rom reference (Jouhet, 2013)).
guration; (ii) Micellar (M)  in which lipids (e.g. lyso-phospholipids
LPL) and gangliosides) form spherical droplets with polar head
roups facing outward and non-polar tails toward the interior;
iii) Inverted micellar (IM) in which lipids (e.g. PE) align to form
nverted spherical droplets in which polar head groups face the
nterior and non-polar head groups face outward; (iv) Hexagonal
r inverted hexagonal (HI or HII) in which lipids (e.g. PE and car-
iolipin (CL)) forming M or IM phases arrange themselves in long
ubular aggregates under certain temperature, pH, or ionic condi-
ions; and (v) Cubic or reverse cubic (QI or QII), in which lipids adopt
n even more complex arrangement (e.g. monoacylglycerol (MAG)
an form a cubic phase which is an intermediate between HII and L
hases). The significance of lipid phases in biological membrane is
iscussed elsewhere (reviewed in Jouhet, 2013); in context of the
usion mechanism, a transient non-lamellar (i.e. high curvature)
emifusion intermediate is one of the lipidic rearrangements said
o underlie membrane fusion (Chernomordik et al., 1995).
. PLA2 and its role in membrane lipid homeostasis
The dynamic equilibrium of membrane lipid constituents is
trongly regulated by the ratio of ‘lamellar’ to ‘non-lamellar’ lipids.
uch control is enabled by lipid modifying enzymes such as Phos-
holipase A2 (PLA2) that hydrolyses membrane phospholipids at
he sn-2 position producing LPL (often LPC) which are preferentially
etained in the membrane, and a polyunsaturated free fatty acid
PUFA) – often Arachidonic acid (ARA; 20:4n-6) – that is somewhat
ore soluble and mobile with flipping efficiency of t(1/2) < 1 s;
amilton, 1998), that can incorporate back into the phospholipids
ia acyl chain remodelling or Lands cycle (Balsinde et al., 1995;
ands et al., 1982). PLA2 constitute a diverse enzyme family which
s divided into groups based on sequence homology, sub-cellular
ocalization, and calcium requirements. Broadly, these include (i)
a2+-dependent secretory forms (sPLA2); (ii) Ca2+-dependent cyto-
lasmic variants (cPLA2); and (iii) Ca2+-independent cytoplasmic
ypes (iPLA2).At steady state, constituent molecular species in the mem-
rane are regulated by interactions between de novo biosynthesis
 Kennedy pathway (Kennedy and Weiss, 1956) – and Lands cycle,
hich is mediated by phospholipases and acyltransferases (i.e.formation of LPL and FFA. The released FFA is converted either to eicosanoids or into
fatty acyl-CoA; the LPL is acylated by acyltransferases using fatty acyl-CoA. (Adapted
from (Balsinde et al., 1995; Kennedy and Weiss, 1956; Lands et al., 1982)).
transacylases) (Fig. 2). In the Kennedy pathway, free fatty acid (FFA)
is converted into fatty acyl-CoA and then to glycerol phosphate or
dihydroxyacetone phosphate (DHAP), resulting in the formation of
PA or lysoPA. The PA is in turn converted to PI or to diacylglyc-
erol (DAG), the latter of which is ultimately converted to PC, PE or
PS. In Lands cycle, such existing phospholipids are hydrolysed to
lyso-PC, −PE and −PS by the action of iPLA2, releasing FFA. The lib-
erated FFA is rapidly converted to acyl-CoA and finally incorporate
back to the membrane via the Lands or Kennedy cycles. The incor-
poration of ARA into different cellular lipids, including signalling
molecules (e.g. eicosanoids) depends upon their concentration; at
nanomolar levels of free ARA, incorporation occurs almost exclu-
sively into membrane phospholipids, while at micromolar levels,
abundant incorporation occurs via the de novo pathway, ultimately
leading to accumulation of ARA in triacylglycerol (TAG) (Balsinde
and Dennis, 1996). TAG lacks a polar head group and instead carries
three acyl chains that contribute to its intrinsic negative curvature.
3. The membrane fusion mechanism: Hypotheses
The prevailing protein-centric model of membrane fusion
is based on the SNARE complex − an assembly of syntaxin,
SNAP 25 (synaptosomal-associated protein, 25 kDa), and synap-
tobrevin/VAMP (vesicle associated membrane protein). All SNARE
proteins contain a defining heptad repeat motif of hydrophobic
residues. VAMP and syntaxin contain one SNARE motif connected
to the C-terminal single trans-membrane domain (TMD) by a short
linker region whereas SNAP-25 contains two SNARE motifs and is
anchored to the membrane via palmitoylation. The cis complex
involves proteins on the same membrane whereas trans SNARE
complexes form between membranes (i.e. syntaxin and SNAP25 in
one bilayer and VAMP in the apposed bilayer), holding the two dis-
tinct membranes together. It is speculated that inter-membrane
‘zippering’ of SNARE motifs, from N- toward C-termini, provides
the necessary energy to facilitate membrane contact and fusion;
that is, the mechanical force generated is postulated to be suffi-
cient to overcome the hydration barrier and initiate formation of
the fusion pore (Jackson, 2010; Min  et al., 2013). Further, it has also
been proposed that the rim of the fusion pore is proteinaceous,
D. Dabral, J.R. Coorssen / The International Journal o









































centrations of FFA (Brash, 2001). Using the activity of native plasmahrough to opening of a fusion pore via high curvature intermediates. (Adapted
rom  references (Churchward Matthew and Coorssen Jens, 2009)).
ormed by the oligomerization of syntaxin TMDs (Han et al., 2004).
owever, there is evidence to indicate that neither the cytoplas-
ic  domains of the SNAREs nor the TMD  of syntaxin are directly
nvolved in membrane fusion (Coorssen et al., 1998; Szule et al.,
003; Zhou et al., 2013; Zick et al., 2014). More recent work also sug-
ests that a single trans SNARE complex may  be sufficient to dock
embranes and promote subsequent fusion, obviating the notion
f a proteinaceous channel-like fusion pore composed of SNARE
MD  (Shi et al., 2012). Furthermore, physiological levels of SNAREs
o not support vacuolar fusion in the absence of negative curva-
ure lipids (Zick et al., 2014). Together, these studies strongly argue
gainst the SNARE-centric model of fusion, but not necessarily of
he critical steps preceding membrane merger. Indeed, we  have
reviously suggested that the trans SNARE complex could be a late
f not the last step of docking and priming, ensuring fast efficient
usion (i.e. membrane merger) upon arrival of an appropriate trig-
er (e.g. calcium) (Coorssen et al., 2003; Coorssen et al., 1998; Szule
t al., 2003).
The lipidic fusion pore model, or stalk-pore hypothesis, pos-
ulates that membrane fusion proceeds through merging of the
roximal monolayers of adherent bilayer membranes followed
y merger of the distal monolayers (i.e. outer leaflets of fusing
ilayers); (Chernomordik et al., 1995). The entire fusion process
roceeds from point of contact, formation of stalk and hemi-fusion
iaphragm (HD), fusion pore opening and expansion, to content
elease or mixing (depending on the nature of the merging targets)
Fig. 3). The energy required to merge membranes is influenced
y the spontaneous curvature of the constituent lipids (Fuller and
and, 2001). Local lipids having intrinsic negative curvature thus
romote merger of proximal leaflets of the contacting bilayers,
eading to the formation of the HD or a localized stalk; introduc-
ion of positive curvature lipids (in particular LPC) at the contact
ite blocks membrane merger (Chernomordik et al., 1995; Vogel
t al., 1993). Under fusogenic conditions, following merger of the
roximal leaflets, distal leaflets merge resulting in formation, open-
ng and expansion of the fusion pore. The merging of the distal
eaflets is promoted by local lipids having net positive curvature.
herefore, membrane fusion proceeds rapidly through transient
igh curvature lipid intermediates. However, lipids may  also havef Biochemistry & Cell Biology 85 (2017) 1–5 3
critical modulatory roles. Some (anionic) lipids are deprotonated,
having a negative charge under physiological conditions, and can
bind di- and trivalent cations, particularly free calcium ions. PS, for
instance, may  locally bind calcium or could modulate Synaptotag-
min  – a putative calcium sensor (Lai et al., 2011; Rogasevskaia et al.,
2012). PA, on the other hand seems to have a role in vesicle dock-
ing and/or priming (Rogasevskaia and Coorssen, 2015; Starr et al.,
2016) . In contrast, cholesterol has both an intrinsic negative curva-
ture and defines membrane microdomains; it can directly facilitate
membrane merger by lowering the energy barrier in the proximal
monolayer mixing (Churchward and Coorssen, 2009; Churchward
et al., 2008; Churchward et al., 2005), and could also promote the
efficiency of the fusion mechanism by maintaining other key com-
ponents in a localized, functional state – the physiological fusion
machine (Churchward et al., 2005; Rogasevskaia et al., 2012).
4. How PLA2 could modulate or facilitate membrane fusion
Studies have suggested a role for PLA2 in regulated exocyto-
sis, and perhaps in membrane merger in neuroendocrine cells, as
treatment with PLA2 inhibitors resulted in blockade of ARA pro-
duction and a parallel inhibition of triggered exocytosis (Ray et al.,
1993). Furthermore, increased synaptic vesicle fusion occurs in pre-
synaptic membranes that are pre-treated with PLA2 (Nishio et al.,
1996). Conversely, there are also data suggesting separation of all
major phospholipase activities from a direct effect on native mem-
brane fusion (Coorssen, 1996).
Exogenous ARA increases catecholamine release from neurose-
cretory cells and has been shown to influence membrane fusion by
enhancing vesicle docking (García-Martínez et al., 2013) perhaps by
enhancing inter-membrane SNARE complex formation (Darios and
Davletov, 2006; Johns et al., 2001; Latham et al., 2007). Munc18, a
regulatory protein in the exocytotic pathway, is known to ‘lock’ syn-
taxin in the closed conformation (Yang et al., 2000); ARA interacts
with the syntaxin/Munc18 complex, relieving syntaxin to engage
in trans-SNARE complex formation (Connell et al., 2007; Rickman
and Davletov, 2005). ARA has been suggested to directly inter-
act with SNARE microdomains, limiting lateral motion of vesicles
that are closer to the PM (Johns et al., 2001). In such lipid supple-
mentation studies, prolonged cell incubations with exogenous ARA
enhanced SNARE complex formation. Under these conditions, ARA
(or indeed any exogenous lipid) could be rapidly metabolized, lead-
ing to accumulation of other Lands or Kennedy cycle intermediates
depending on the rate limiting step(s) of the pathways; it is thus
unclear whether ARA was  the active lipid species in these studies.
It would therefore be of interest to investigate the effect of PLA2
derived endogenous ARA on SNARE complex formation and subse-
quent membrane fusion. Furthermore, since Phospholipase D (PLD)
derived PA has a role in docking and priming (Rogasevskaia and
Coorssen, 2015) and interactions between PLA2 and PLD are also
indicated (Wang et al., 1999) both phospholipases may  have inter-
acting roles in maintaining the docked, primed, fusion-ready state.
It is also important to establish local concentrations of LPL and FFA
species under conditions of both PLA2 inhibition and stimulation,
and to test for an increase or decrease, respectively, in exocytotic
release.
The membrane concentration of LPC species required for ∼50%
inhibition of exocytotic fusion is ∼1-2 mol% (Chernomordik et al.,
1997). The resting concentration of arachidonic acid per cell is in
the pico-to-nanomolar range; the release of even 1% of the total
esterified pool of arachidonate could yield up to 50 M local con-membrane PLA2 (human polymorphonuclear leukocytes; Victor
et al., 1981) and the levels of PC and PE in both plasma and cortical
secretory vesicle membranes (Kinsey et al., 1980; Churchward et al.,











































ig. 4. a. Non-contacting membranes; b. membranes in close proximity. Working
RA;  LPL acts as a local ‘fusion block’ inhibiting the premature (i.e. pre-stimulus) m
aintaining the fully primed, fusion-ready state.
008a), one can estimate that the levels of LPC and LPE produced
n the PM would be ≤0.162 and ≤0.61 nmoles/h/100 g protein,
espectively, and ≤0.14 and ≤0.04 mol%/h, respectively, in the vesi-
le membrane. It is also noteworthy that further metabolism of
hese LPL is unlikely to be uniform and this will also have a sub-
tantial impact on their lifetimes, as will the extent to which the
LA2 activities may  be localized at the docking/fusion sites. Fur-
hermore, the characteristic flip-flop rate of LPCs is estimated in
ours (Chernomordik et al., 1997), thus further emphasizing the
ignificance of PLA2 localization activity at the inner monolayer of
he PM and the outer monolayer of the vesicle membrane yields
proximal’ LPC that would block fusion.
Therefore, with reference to the Stalk-pore hypothesis as well
s evidence suggesting a stimulatory effect of ARA on SNARE com-
lex formation, we propose that localized PLA2 produce LPL that
ct as a basal local fusion ‘block’ or ‘brake’ inhibiting the premature
erging of the proximal membranes, and ARA (or an active down-
tream metabolite) supports the SNAREs in maintaining a docked,
rimed state (Fig. 4). This implicates PLA2 species as critical com-
onents of the physiological fusion machine, and one or more of
heir metabolites as potentially critical to the physiological fusion
echanism.
. Conclusion and perspective
The actual role of SNAREs in membrane fusion has been debated,
lthough even in the most extreme interpretation of their functions,
usion must still involve lipid mixing to effect membrane merger.
t is nonetheless evident that lipids and proteins play integral and
ntegrated roles in docking, priming, and membrane fusion. Lipids
acilitate membrane bending by virtue of their intrinsic sponta-
eous curvature, form microdomains enriched in priming and/or
ocking factors, and also constitute critical interaction/binding
ites for important protein components. There may  well also be
ther important, yet undiscovered lipid-protein interactions that
lay modulatory or direct roles in membrane fusion. Thus, as out-
ined in Sections 3 and 4, PLA2 derived endogenous ARA together
ith the SNAREs could play an integral role in docking and prim-
ng, while the LPC produced in parallel would serve as a local fusion
lock until such time as an appropriate trigger initiates rapid mem-
rane merger. Studies of PLA2 in local lipid homeostasis and the
otential functions of its metabolites in maintaining the fusion-
eady state and modulating membrane merger are thus warranted,hesis: a fusion ready state is maintained by localized PLA2 that produces LPL and
r of the proximal membranes while ARA supports the trans SNARE complex(es) in
particularly with regard to understanding modified membrane
interactions in disease states.
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Abstract: The fundamental molecular mechanism underlying the membrane merger steps of regulated
exocytosis is highly conserved across cell types. Although involvement of Phospholipase A2 (PLA2) in
regulated exocytosis has long been suggested, its function or that of its metabolites—a lyso-phospholipid
and a free fatty acid—remain somewhat speculative. Here, using a combined bioinformatics and
top-down discovery proteomics approach, coupled with lipidomic analyses, PLA2 were found to
be associated with release-ready cortical secretory vesicles (CV) that possess the minimal molecular
machinery for docking, Ca2+ sensing and membrane fusion. Tightly coupling the molecular analyses
with well-established quantitative fusion assays, we show for the first time that inhibition of a CV
surface calcium independent intracellular PLA2 and a luminal secretory PLA2 significantly reduce
docking/priming in the late steps of regulated exocytosis, indicating key regulatory roles in the critical
step(s) preceding membrane merger.
Keywords: membrane merger; secretory vesicles; lysolipids; free fatty acids; regulated secretion; fusion
1. Introduction
Fusion is a ubiquitous fundamental cellular process enabling merger of biological membranes; this
includes the defining release step of exocytosis following merger of secretory vesicles with the plasma
membrane (PM). Studies over the last three-four decades have suggested a role of Phospholipase
A2 (PLA2) in regulated exocytosis, generally arising from correlations of arachidonic acid (ARA)
levels and vesicle content release [1–8]. In a cell free system, fusion of secretory vesicles with target
membranes increased in the presence of PLA2 suggesting that the enzyme or its metabolites affected
membrane merger or the steps immediately preceding it [5,6,9]. Furthermore, addition of exogenous
PLA2 metabolites inhibits hemi-fusion formation or transition from hemi-fusion to pore opening
depending upon their site of incorporation [10–12]. That PLA2 species have been identified in secretory
vesicles isolated from neutrophils [13], chromaffin cells [14], insulin secreting cells [15,16] and mast
cells [17,18] highlights that these are conserved protein components of secretory vesicles. Early studies
also identified endogenous PLA2 activity in purified synaptic vesicles (SV) [5,6,19,20]. While some
proteomic analyses have failed to identify SV associated PLA2 [21,22], suggesting very low abundance
and/or activity, at least one study identified iPLA2γ in synaptosomes [23]. Indeed, when synaptosomes
were fractionated into free and docked SV pools prior to proteomic analysis, a patatin-like phospholipase
domain containing 8 (Gene ID 157819923; also known as iPLA2γ) was found to be more abundant in
the docked SV pool [24].
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Based on subcellular localization and Ca2+ requirement, PLA2 isozymes are broadly classified as
(i) Ca2+-dependent secretory or sPLA2, (ii) Ca2+-independent cytoplasmic or membrane bound iPLA2
and (iii) Ca2+-dependent cytoplasmic or cPLA2. Nevertheless, all PLA2 cleave membrane phospholipids
at the sn-2 position, producing a lyso-phospholipid (often lyso-phosphatidylcholine; LPC) which
is preferentially retained in the membrane and a diffusible free fatty acid (FFA; often arachidonic
acid (ARA; 20:4n-6)) that can incorporate back into the membrane via Lands cycle intermediates
or is further metabolized to yield eicosanoids. sPLA2 are generally 12–19 kDa proteins containing
5–7 conserved disulphide bonds and are characterized by an active site histidine in a DXCCXXHD
consensus sequence and a conserved Ca2+-binding loop with a XCGXGG consensus sequence [25,26].
Once secreted, their Ca2+ requirement for catalysis is in the low millimolar (mM) range with no
strict fatty acid selectivity, although mostly target phosphatidyl-ethanolamine, -glycerol, -inositol
and -serine (PE, PG, PI and PS) [26,27]. Although these enzymes are generally thought to be active
only when released into the extracellular space, the possibility of basal sPLA2 activity in the vesicle
lumen has been suggested [17,28,29]. In transfected CHO-K1 and HEK293 cells that lack regulated
secretory vesicles, expressed sPLA2 was localized to the golgi and related intracellular vesicles and
released ARA, indicating basal activity [28]. Of note is that adequate concentrations of free calcium
([Ca2+]free) may be (transiently) present within regulated secretory vesicles to support luminal sPLA2
activity under basal conditions [30–33]. In contrast, iPLA2 are intracellular enzymes that do not
require Ca2+ beyond basal cytosolic levels for activity, contain serine in the GXSXG active site and
possess a nucleotide-binding (GXGXXG) consensus sequence. The mammalian forms include iPLA2β,
iPLA2γ, iPLA2δ, iPLA2ε, iPLA2ζ and iPLA2η with molecular weights ranging from 27 to 146 kDa.
A well-established function of iPLA2β is membrane phospholipid remodelling via Lands cycle to
maintain membrane integrity [29,34,35]. cPLA2 are cytosolic proteins of molecular weights ranging
from 61-114 kDa and require micromolar [Ca2+]free for association with membrane phospholipids via
their N-terminal C2 domain [25,26]. These enzymes also carry serine at GXSXG, GXSGS or GXSXV
lipase consensus sequences [36]. There are six mammalian cPLA2 isoforms, cPLA2-α, β, γ, δ, ε, ζ of
which all except cPLA2γ have a N-terminal C2 domain [36,37].
At the genomic level, sea urchin and human remain closely related (both are deuterostomes)
relative to invertebrates [38–40]. SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein
receptor) proteins are highly conserved across species, having been identified on exocytotic vesicles
from yeast to man, including the release-ready cortical vesicles (CV) isolated from unfertilized sea urchin
eggs [40–46]. Furthermore, as CV retain the minimal molecular machinery for docking, Ca2+ sensing
and membrane fusion, they are a well-established model to study the late steps of Ca2+-triggered
exocytosis [42,43,45,47–54]. CV are easily isolated with high purity and yield, either endogenously
docked on the PM (i.e., cell surface complexes; CSC) or free-floating [42,49,51,55]. On triggering with
Ca2+, isolated CV fuse with each other in a manner indistinguishable from CV-PM fusion [42,45,49,55].
Using these fusion-ready native vesicles, we first identified catalytically active endogenous PLA2
isozymes using a combined bioinformatics and top-down discovery proteomics approach coupled
with lipidomic analyses. We then asked whether these isozymes have a role in the late steps of
Ca2+-triggered exocytosis. The enzymatic activities were localized to the CV lumen and vesicle surface
and tightly coupled functional and molecular analyses were carried out to assess these PLA2 activities
and their associated effects on fusion parameters. A modulatory role in priming and/or docking
is indicated.
2. Materials and Methods
2.1. Materials
2.1.1. Assessment of PLA2 Activities and Fusion Assays
Native sea urchins (Heliocedaris tuberculata) were maintained at 7–8 ◦C in the local aquatic facility.
CSC and CV were isolated as previously described [38,41,42,45,51,52,55]. Bromoenol lactone (BEL)
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and 3-(3-acetamide-1-benzyl-2-ethylindolyl-5-oxy) propane sulfonic acid (LY311727) were purchased
from Sigma Aldrich (St. Louis, MO USA); 1,1,1,2,2-Pentafluoro-7-phenyl-3-heptanone (FKGK-11) was
from Cayman Chemicals (Ann Arbor, MI, USA).
CSC membrane labelling was carried out using 1-oleoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)
amino] dodecanoyl} -sn-glycero-3-phospho-choline/-ethanolamine (NBD-PC/PE). Quantification of the
generated NBD-FFA and NBD-PA was done using 1-oleoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)
amino Arachidonic acid 20:4 (NBD-ARA) and 1-oleoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl) amino]
dodecanoyl}-sn-glycero-3-phosphate (NBD-PA) as reference standards. ARA (20:4) was purchased
from Matreya LLC (State college, PA, USA) while all other lipids were purchased from Avanti Polar
Lipids (Alabaster, AL, USA). Quantitative lipid analyses were carried out using High Performance
Thin Layer Chromatography (HPTLC) [49–51,56]. Silica G-60 plates were purchased from Merck
Millipore Ltd. (Darmstadt, Germany). All HPTLC solvents were minimally of analytical grade.
High grade Trypsin was from Promega Corp. (Madison, WI, USA). The selective PLA2 substrate,
PED6 (N-((6-(2,4-Dinitrophenyl) amino) hexanoyl)-2-(4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-
Indacene-3-Pentanoyl)-1-Hexadecanoyl-sn-Glycero-3-Phosphoethanolamine, Triethylammonium Salt)
was from Invitrogen (Carlsbad, CA, USA).
2.1.2. Protein Fractionation, Gel Electrophoresis and Western Blotting
Amicon Ultra-4 centrifugal filters (3kDa cut-off) came from Merck Millipore. Constituents of the
Protease inhibitor cocktail [41,57] were purchased from Sigma-Aldrich (St. Louis) and AMRESCO Inc.
(Dallas, TX, USA). All electrophoresis grade chemicals used in two-dimensional gel electrophoresis
(2DE) were purchased from AMRESCO Inc. 3-10NL IPG strips, tributyl phosphine and Polyvinylidene
difluoride (PVDF) membrane (0.2 µM pore size) were from Bio-Rad (Hercules, CA, USA). Anti-human
rabbit polyclonal iPLA2 antibody (PA5-27945) and anti-human mouse monoclonal sPLA2 antibody
(ab-24498) were from Invitrogen and Abcam (Cambridge, UK), respectively. Blocking agents—non-fat
dry milk powder and BSA—were from Devondale (Saputo Dairy, Australia) and Sigma Aldrich,
respectively. HRP linked anti-mouse IgG (NA93IV) and anti-rabbit IgG (NA934VS) antibodies
came from GE Healthcare (Buckinghamshire, UK). Lumunata Cresendo Western HRP substrate was
purchased from Merck Millipore. The blots and gels were imaged using the Image Quant™ LAS 4000
Biomolecular Imager (GE Healthcare, Chicago, Il, USA).
2.2. Methods
2.2.1. Molecular Analysis to Detect CSC Associated PLA2 Activities
PLA2 activities in intact unlabelled CSC suspensions (0.5 mL, OD 0.56 ± 0.02, n = 3–14) were
assessed by measuring changes in FFA following treatments with the indicated concentrations of
BEL, LY311727 and FKGK-11; exploratory experiments (n = 1–2) with 40 µM BEL, 10 µM FKGK-11,
100 nM LY311727 and higher concentrations were first carried out. Only those concentrations that
significantly reduced endogenous FFA relative to control were selected for further study. CSC were
isolated according to established protocols [49–52] and suspended in baseline intracellular medium
(BIM; 210 mM potassium glutamate, 500 mM glycine, 10 mM NaCl, 10 mM PIPES, 50 µM CaCl2,
1 mM MgCl2, 1 mM EGTA pH 6.7) supplemented with 2.5 mM ATP, 2 mM DTT and 1X protease
inhibitors [41–43,45,51,52]. Stock solutions of inhibitors were prepared in dimethyl sulfoxide and were
delivered to CSC suspensions at a final solvent concentration of <1% [48,51,52]. At the end of the
incubation, CV suspensions were immediately placed on ice, diluted with 5–8 mL of ice-cold BIM and
aliquoted for rapid isolation of total lipids and for immediate assay of CV-PM fusion [49–51].
In separate experiments, CSC were allowed to incorporate NBD-PC or -PE for 15 min prior to the
20 min inhibitor treatments. Briefly, CSC suspensions (7 mL, OD 0.56 ± 0.005, n = 3) were labelled with
5600 picomoles NBD-PC or -PE for 15 min followed by treatment with the indicated doses of inhibitors.
At the end of the treatments, all aliquots were washed three times in ice-cold BIM (pH 6.7) to remove
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unlabelled NBD substrate and inhibitors and immediately placed on ice prior to rapid isolation of total
CSC lipids and membrane proteins (see Section 2.2.4).
2.2.2. Quantitative Lipid Analyses
Total CSC or CV lipids were extracted according to Bligh and Dyer with established
modifications [50–52,56,58]; total CV membrane proteins were also isolated from parallel aliquots by
lysing CV with ice-cold PIPES (see Section 2.2.4). The resulting organic phases (and also aqueous phases
in scaled-up experiments) were recovered, dried under nitrogen and suspended in CHCl3:CH3OH
(2:1; v/v) for loading onto pre-conditioned silica gel 60 HPTLC plates. Sample loading was with the
CAMAG automatic TLC sampler. Pre-conditioning of the plates was as previously described [50–52,56].
Using the CAMAG AMD 2 multi-development unit, neutral- and phospho-lipids were resolved
using optimized protocols [48,49,51,52,56]. Resolved lipids were visualized on-plate by charring
homogenously wetted plates with 10% cupric sulphate in 8% aqueous phosphoric acid at 145 ◦C
for 10 min [56]; imaging was at 460 nm/605 nm (Ex/Em) using the LAS 4000 Biomolecular Imager
and was analysed using MultiGauge v3.0 (Fuji Photo Film Co., Ltd. Tokyo, Japan). Quantification
of endogenous CV or CSC lipids, NBD-FFA and -PA, was via calibration curves of the appropriate
standards, resolved by HPTLC, in parallel with the experimental samples. To resolve neutral and
phospholipids, well-established protocols were used [56]; NBD-FFA and -PA generated from NBD-PC
labelled CSC were resolved together after confirming that the standard neutral lipid protocol was
satisfactory for resolving both these species. To measure fluorescent signal from NBD-labelled lipids,
uncharred plates were imaged at 460 nm/575 nm (Ex/Em) using the same imager and analysis software.
2.2.3. Sequence Alignments
To identify regions of homology, a sequence alignment of the putative urchin sPLA2 (W4XE93) and
iPLA2 (XP_011669048.1) relative to characterized human and mouse isoforms was carried out using
MEGA version 7.0.21 (free software downloaded from https://www.megasoftware.net/home) [59,60] and
the ClustalW algorithm with default settings. All protein sequences, except that of the predicted urchin
iPLA2, were downloaded from Uniprot (February 2019). Of 22 putative urchin sequences, one with
sPLA2 characteristics (i.e., ~14kDa, likely to form intra-molecular disulphide bonds and prediction of
Ca2+ as a cofactor [17,25]) was selected using the information available in Uniprot. Similarly, a putative
urchin 80–85kDa iPLA2 was selected from the 44 entries on the basis of characteristic molecular weight
and presence of ankyrin repeats—a feature common to iPLA2 forms across species [25,35]. As the
predicted urchin 80–85kDa iPLA2 is not present in the Uniprot database, the sequence was downloaded
from PubMed. Human PLA2 sequences used for the analyses were sPLA2–P14555 and iPLA2–O60733
and murine PLA2 sequences were sPLA2–Q9WVF6 and iPLA2–P97819. Only those human and murine
PLA2 sequences identified at the protein level were selected. As the predicted urchin sequences present
in Uniprot or PubMed (66 sequences in total) do not contain the C2 domain characteristic of cPLA2,
sequence alignment of cPLA2 isozymes was not carried out and there was no further testing for this
isozyme. Building from the in-silico analysis, validation at the protein level was then carried out using
a well-established top-down proteomic approach coupling 2DE with high-sensitivity western blotting
using anti-human sPLA2 and iPLA2 antibodies to conserved regions [45,57,61].
2.2.4. Sample Fractionation for 2DE Western Blotting
After de-jellying and thorough washing, unfertilized urchin eggs were homogenized in intracellular
media (IM; 220 mM K-glutamate, 500 mM glycine, 10 mM NaCl, 5 mM MgCl2, 5 mM EGTA, pH 6.7)
supplemented with 2.5 mM ATP, 1 mM benzamidine HCl, 2 mg/mL aprotinin, 2 mg/mL pepstatin,
2 mg/mL leupeptin and 2 mM DTT) prior to standard isolation of high purity CSC or CV suspended in
BIM [38,42,45,47–49,51,52]. For fractionation, CV were lysed using three volumes of ice-cold PIPES
buffer (20 mM PIPES, pH 7.0 supplemented with protease, phosphatase and kinase inhibitors) for
90 s and isotonicity restored by adding an equal volume of 2 X IM (supplemented with protease,
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phosphatase and kinase inhibitors). Samples were centrifuged at 125,000× g, 4 ◦C, for 3 h to recover
membrane pellets and CV luminal proteins in the supernatant [50]. Membranes were solubilized in
2DE buffer (4% CHAPS, 8 M Urea and 2 M Thiourea supplemented with protease, phosphatase and
kinase inhibitors [50,57]) while supernatant containing CV luminal proteins was buffer exchanged
with 3M urea solution using Amicon filters. Solubilized membrane proteins and concentrated CV
luminal proteins were resolved using a well-established 2DE protocol involving isoelectric focusing
(IEF) followed by SDS-PAGE in 1 mm thick 10% resolving gels [57]. Subsequent high sensitivity
western blotting was essentially as previously described [41,42,45,61]. Briefly, resolved proteins were
transferred to 0.2 µM pore size PVDF membrane (Bio-Rad) using buffer containing 25 mm Tris, 192 mm
glycine, 20% methanol and 0.025% SDS at 90 Volts for 1 h. Blots were blocked for 1 h at room
temperature (RT) in a solution containing 20 mM Tris, 150 mM NaCl, 0.1% Tween (TBST) and 5%
non-fat dry milk or 20 mg/mL BSA. Blots were incubated overnight (at least 16 h) with constant rocking
at 4 ◦C with anti-human sPLA2 (1:800) or iPLA2 (1:2000) primary antibodies. After washing, blots were
incubated with secondary antibodies conjugated to horseradish peroxidase (HRP) for 2 h at RT and
then detected using Luminata Crescendo western HRP substrate and the LAS 4000 Biomolecular
Imager. Secondary antibody controls were always carried out in parallel western blots and parallel
2DE gels were stained with colloidal Coomassie Brilliant Blue (cCBB) [62,63].
2.2.5. Molecular Analyses to Detect CV Associated PLA2 Activities
Membrane and luminal fractions from purified CV suspensions were isolated using the same
overall strategy as above except for the use of ice-cold BIM (pH 6.7) in the last step to maintain
endogenous PLA2 activity. This also ensured tight coupling of functional (i.e., fusion) and molecular
analyses. PLA2 activity in CV membrane and lumen fractions was measured by incubating 30 µg CV
membrane or luminal protein with 200 picomoles NBD-PE or 170 picomoles NBD-PC for 30 s–10 min.
PLA2 activity was then stopped by adding 0.2 µL HCl and all aliquots were immediately placed on
ice for rapid isolation of total lipids; scaled-up experiments were carried out using more CV luminal
protein (120 µg) and NBD-PE (664 picomoles) to best detect NBD-FFA species. An equal volume of
BIM without CV luminal or membrane protein was used as a control to which the indicated amount of
NBD-PC or -PE was added and incubated for 10 min.
To further establish whether catalytically active PLA2 was on the outer CV monolayer,
well-established trypsin treatments were carried out to remove CV surface proteins and PLA2
activity was measured using the selective PLA2 substrate, PED6. Briefly, CV suspensions (2–4 mL;
OD 0.95 + 0.04; n = 3) were treated with 700 U/mL trypsin for 1 h with gentle mixing every 15 min [42,45].
After treatment, CV suspensions were aliquoted into microplates and incubated with PED6 for 0–30 min;
PLA2 activity was measured at 485 nm/520 nm (Ex/Em) using a POLARstar Omega microplate reader.
Fusion assays were also carried out to confirm the fusion competence of the treated CV. To confirm
removal of iPLA2 from the CV surface, western blotting was carried out on CV membrane proteins using
the iPLA2 antibody. Protein isolation and SDS-PAGE were as above with the exception that SDS sample
buffer was used for solubilizing CV membrane proteins and detection was with cCBB [41,42,45,62,63].
In parallel replicates, absorbance at A405 was measured regularly during the incubations to assess for
possible CV lysis; any drastic decrease in absorbance indicated marked loss of CV due to bursting
(as seen with the addition of ddH2O at the end of the experiment to confirm the intact state of CV).
2.2.6. Effects of PLA2 Activities on Fusion Assays
Standard fusion and docking/priming assays were carried out as previously described [42,43,45,
47–52,54,56]. All experiments were carried out in BIM pH 6.7 supplemented with 2.5 mM ATP, 2 mM
DTT and 1X protease inhibitors [41–43,45,51,52]. Briefly, CSC (0.5 mL, OD 0.56 ± 0.02, n = 3–14) and
CV (OD 0.94 ± 0.03, n = 22) suspensions were treated with the indicated inhibitor concentrations.
Immediately following treatments, suspensions were diluted with 3–5 volumes of ice-cold BIM, pH 6.7
and aliquoted into microplates. Each condition was challenged with increasing concentrations of
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[Ca2+]free in quadruplicate, consistent with established protocol and this was repeated in separate
experiments as indicated (n) [42,43,45,47–52]. The decrease in OD representing CV fusion was measured
using a POLARstar Omega microplate reader [53,54]. Final [Ca2+]free were measured with a Ca2+
sensitive electrode (Calcium Combination ISE, EDT directION Limited) as previously described [53,54].
All treatments were carried out at 25 °C. Parallel solvent controls were carried out in every experiment.
A separate aliquot in each experiment was also snap-frozen in liquid N2 and stored at −80 °C for
subsequent molecular analyses.
3. Data Analyses
All data are reported as mean ± S.E.M. Two-sample two-tailed t-tests and 2-way ANOVA with
Tukey’s multiple comparisons were performed using GraphPad PRISM 7 version 7.04 to assess the
difference between experimental conditions (p ≤ 0.05 are considered significant).
4. Results
4.1. Identification of Endogenous PLA2 Activities on CSC and Their Effects on CSC Fusion
As CSC consist of CV endogenously docked on the PM and undergo Ca2+-triggered exocytosis
in vitro, the potential presence and influence(s) of PLA2 activities was first assessed using CSC and selective
PLA2 inhibitors. Treating CSC with LY311727 and BEL caused significant concentration-dependent
decreases in endogenous FFA levels relative to a basal FFA level of 267.8 ± 29.8 femtomoles per µg
CSC membrane protein (fmoles/µg MP) (Figure 1A; n = 3); 200 µM LY311727 reduced FFA levels
to 122.7 ± 20.13 fmoles/µg MP while 100 µM and 500 µM BEL treatments reduced FFA levels below
background values. No significant change in FFA levels was observed in any of the FKGK-11 treatments.
As the lipid detection approach used is somewhat selective for unsaturated lipid species [56], in order
to ensure a full assessment of potential PLA2 activities, CSC were labelled with NBD-PC (fluorophore
at the sn-2 fatty acid); as previously documented, such exogenous substrates are readily incorporated
into CSC and CV membranes [49]. The generation of 3.8 ± 1.2 picomoles NBD-FFA/µg MP from
hydrolysis of the incorporated NBD-PC further confirmed endogenous PLA2 activity (Figure 1B; n = 3).
The NBD-FFA was also generated from NBD-PE labelled CSC and CV (n = 1 confirmatory experiment,
not shown). However, in contrast to Figure 1A, treating NBD-PC labelled CSC with increasing doses of
BEL resulted in a concentration-dependent increase in NBD-FFA to 7.2 ± 3.0 and 9.8 ± 2.9 picomoles/µg
MP. Similarly, a concentration-dependent increase in NBD-FFA to 8.9 ± 6.4 and 11.5 ± 8.2 picomoles/µg
MP was observed in NBD-PC labelled CSC treated with 50 µM and 200 µM FKGK-11, respectively.
No significant change in NBD-FFA levels were observed in any of the LY311727 treatments. As PLD
also acts on PC, generation of 2.8 ± 0.5 picomoles NBD-PA/µg MP confirmed endogenous PLD activity
(Figure 1B) consistent with previous findings [49]. However, none of the inhibitors caused significant
change in NBD-PA with respect to the control. Importantly, the decrease in endogenous FFA levels
(Figure 1A) and an increase in endogenous TAG, the de novo metabolite ([50,56]; Supplementary
Figure 1A and also see [34,64,65]) in the BEL treated unlabelled CSC indicated the presence of a BEL
sensitive PLA2 on CSC. However, the significant increase in NBD-FFA levels in BEL and FKGK-11
treated NBD-PC labelled CSC also indicated the presence of a BEL insensitive PLA2 species (Figure 1B).
As BEL and FKGK-11 inhibit iPLA2 and LY311727 is a selective inhibitor of sPLA2 [26,35,64,66–68],
the data suggested the presence of different catalytically active endogenous PLA2 in CSC preparations.
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Figure 1. Detection and quantification of (A) endogenous CSC FFA, n = 3 separate experiments; (B) NBD-
FFA and -PA in intact CSC after 15 min labelling with NBD-PC followed by 20 min inhibitor treatments, 
n = 3 separate experiments; (C) total CSC neutral lipids visualized on the same TLC plate as shown in B, 
after charring with CuSO4. This also confirmed consistent lipid loading in each lane. Representative 
chromatograms showing indicated changes in lipids. (p-value, * < 0.05, ** < 0.005, **** < 0.0001 indicates 
relative difference to the control). Note: A section of chromatogram is shown in A and lanes in all 
chromatograms are grouped together from the same HPTLC plate following removal of lanes not 
associated with this study. A standard neutral lipid protocol was used to resolve the lipids [56]. 
With the evidence of active endogenous PLA2, the effects of selective PLA2 inhibitors were then 
tested on CV-PM fusion. The native, docked CV-PM preparations exposed to increasing [Ca2+]free 
undergo exocytosis in vitro yielding a classic sigmoidal Ca2+ activity curve with an EC50 of 38.9 ± 6.4 
µM [Ca2+]free (Figure 2; n = 14) [42,45,48,49,52,69,70]. Treating CSC with 20 µM and 200 µM LY311727 
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= 3–4). On treating CSC with 100 µM and 500 µM BEL [35,64,71,72] a significant decrease in the fusion 
extent to 53.7 ± 24.6% and 54.2 ± 7.9%, respectively, was observed; 500 µM BEL also caused a 
progressive rightward shift in Ca2+ sensitivity to an EC50 of 230.6 ± 101.5 µM [Ca2+]free (Figure 2; n = 
3). CSC treated with 50 µM and 200 µM FKGK-11, another iPLA2 inhibitor [67], also significantly 
reduced fusion extent to 71.4 ± 28.5% and 31.3 ± 23.6%, respectively (Figure 2; n = 3). Although, 
LY311727, BEL and FKGK-11 inhibited endogenous FFA production and blocked triggered fusion; 
PLA2 species inhibited by LY311727 seem separate from the species which was inhibited by BEL and 
FKGK-11, in particular with reference to NBD-FFA generated from exogenous NBD-PC. 
Figure 1. Detection and quantification of (A) endogenous CSC FFA, n = 3 separate experiments;
(B) NBD-FFA and -PA in intact CSC after 15 min labelling with NBD-PC followed by 20 min inhibitor
treatments, n = 3 separate experiments; (C) total CSC neutral lipids visualized on the same TLC plate
as shown in B, after charring with CuSO4. This also confirmed consistent lipid loading in each lane.
Representative chromatograms showing indicated changes in lipids. (p-value, * < 0.05, ** < 0.005,
**** < 0.0001 indicates relative difference to the control). Note: A section of chromatogram is shown
in A and lanes in all chromatograms are grouped together from the same HPTLC plate following
removal of lanes not associated with this study. A standard neutral lipid protocol was used to resolve
the lipids [56].
With the evidence of active endogenous PLA2, the effects of selective PLA2 inhibitors were
then tested on CV-PM fusion. The native, docked CV-PM preparations exposed to increasing
[Ca2+]free undergo exocytosis in vitro yielding a classic sigmoidal Ca2+ activity curve with an EC50 of
38.9 ± 6.4 µM [Ca2+]free (Figure 2; n = 14) [42,45,48,49,52,69,70]. Treating CSC with 20 µM and 200 µM
LY311727 [66,68] significantly decreased fusion extent to 44.1 ± 5.3% and 33.6 ± 20.8%, respectively
(Figure 2; n = 3–4). On treating CSC with 100 µM and 500 µM BEL [35,64,71,72] a significant decrease in
the fusion extent to 53.7 ± 24.6% and 54.2 ± 7.9%, respectively, was observed; 500 µM BEL also caused
a progressive rightward shift in Ca2+ sensitivity to an EC50 of 230.6 ± 101.5 µM [Ca2+]free (Figure 2;
n = 3). CSC treated with 50 µM and 200 µM FKGK-11, another iPLA2 inhibitor [67], also significantly
reduced fusion extent to 71.4 ± 28.5% and 31.3 ± 23.6%, respectively (Figure 2; n = 3). Although,
LY311727, BEL and FKGK-11 inhibited endogenous FFA production and blocked triggered fusion;
PLA2 species inhibited by LY311727 seem separate from the species which was inhibited by BEL and
FKGK-11, in particular with reference to NBD-FFA generated from exogenous NBD-PC.
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consistent with a high overall conservation from urchin to human (Figure 3) [40,73,74]. The urchin 
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histidine in the Ca2+ binding loop with a XCGXGG consensus sequence to which LY311727 binds to 
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characteristic GGGVKG consensus sequence [35,75] and a caspase catalytic site with the DVTD 
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Figure 2. Effects of LY311727 (selective for sPLA2) and BEL and FKGK-11 (both selective for iPLA2) on
(A) CSC Ca2+ activity curves (i.e., exocytosis in vitro); (B) fusion extent and; (C) Ca2+ sensitivity (EC50);
n = 3–14. (p-value, * < 0.05, *** < 0.0005, **** < 0.0001 indicates difference relative to the control).
4.2. In-Silico Analysis
With initial evidence indicating the likely presence of more than one PLA2 isozyme on CSC and
their potential role in regulating late steps of regulated exocytosis, we sought to identify these isozymes,
beginning with sequence alignment to identify regions of homology in putative urchin PLA2 and
characterized human and murine forms. The sequence alignment of sPLA2 and iPLA2 in the selected
species clearly indicated conserved amino acid residues throughout the primary amino acid sequences,
consistent with a high overall conservation from urchin to human (Figure 3) [40,73,74]. The urchin
sPLA2 and iPLA2 forms showed high identity and similarity with both the human and murine species,
particularly around the catalytic site histidine with >75% identity and similarity, as well as around
the catalytic site serine with 100% identity and similarity (Figure 3A,B and Table 1). The sPLA2 also
have a histidine in the Ca2+ binding loop with a XCGXGG consensus sequence to which LY311727
binds to inhibit the enzyme [66,68]. The putative urchin iPLA2 also contains a nucleotide binding site
with a characteristic GGGVKG consensus sequence [35,75] and a caspase catalytic site with the DVTD
consensus sequence [35,76,77]. Cysteine residues at C-67, C-185, C-240, C-344, C-465, C-550 and C-821
in the putative urchin iPLA2 are also conserved and are thus likely susceptible to alkylation during
BEL treatments [78].








Urchin Isozymes (Full Length) (at Histidine Catalytic Site)
sPLA2
Human 39 50 68 67
Murine 36 46 74 74
(Full Length) (at Serine Catalytic Site)
iPLA2
Human 36 52 100 100
Murine 36 53 100 100
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Figure 3. Sequence alignment of predicted urchin (A) sPLA2 and (B) 80–85 kDa iPLA2. The first row in 
each panel is the amino acid sequence of urchin PLA2 isozymes and the subsequent two rows are of 
murine and human PLA2 isozymes, respectively. Conserved amino acids are indicated with an asterisk 
and site # represents the amino acid residue number in the primary urchin PLA2 sequence (also 
considering gaps). The red arrow indicates conserved Histidine in the Ca2+ binding loop (Black box), the 
site at which LY311727 binds. Black arrows show conserved Histidine and Aspartic acid which form the 
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and site # represents the amino acid residue number in the primary urchin PLA2 sequence
(also considering gaps). The red arrow indicates conserved Histidine in the Ca2+ binding loop
(Black box), the site at which LY311727 binds. Black arrows show conserved Histidine and Aspartic acid
which form the catalytic site His-Asp dyad. Blue and red boxes indicate the caspase cleavage site and
the active site serine in the GXSXG consensus sequence, respectively. The circle indicates the nucleotide
binding site. Dissimilar residues with the same background colour indicate conservative substitution.
4.3. Western Blotting and Assays to Confirm Identity and Localization of PLA2 Isozymes
After identifying conserved catalytic and regulatory domains in the putative urchin isozymes
(Figure 3 and Table 1), enzyme localization in CSC and CV was probed using selective antibodies.
The anti-human sPLA2 antibody was raised against the entire length of human sPLA2 and would
thus identify putative urchin sPLA2 considering the high identify and similarity, particularly within
the catalytic region (Figure 3A and Table 1). Similarly, the anti-human iPLA2 recognizes a region
between amino acid 399–704, which is also highly conserved in the putative urchin iPLA2 isozyme
(54% identify, 67% similarity); this region also carries highly conserved GXSXG and GGGVKG catalytic
and nucleotide binding consensus sequences (Figure 3B and Table 1). Western blotting of 2D gels
identified two immune positive spots of ~14 kDa and pI of ~4.0 and ~4.9 in the CV lumen fraction
using the sPLA2 antibody (Figure 4A). An immune positive spot of ~63 kDa and pI ~6.2 and two
immune positive spots of ~63 kDa and pI ~5.2 and 5.4 were detected in the CSC and CV membrane
fractions, respectively, using the iPLA2 antibody (Figure 4B,C, respectively). Of note is the relative
high abundance of iPLA2 on the CSC membrane in comparison to the CV membrane.
To further and more specifically localize the PLA2 isozymes and explore possible substrate
preferences, NBD-PE and -PC were used to assess the CV associated enzyme activities. First, an isolate
of CV lumen proteins was incubated with NBD-PE or -PC for different interval (Figure 5A; n = 3).
The NBD-PE in controls after 10 min incubation was 12.3 ± 0.9 picomoles which was significantly
reduced to 9.0 ± 1.2, 7.4 ± 1.2, 6.8 ± 1.0 and 3.8 ± 2.3 picomoles following 30 s, 2 min, 5 min and 10 min
incubations, respectively (Figure 5A). The generation of NBD-FFA having a retention factor (Rf) similar
to NBD-ARA indicated PLA2 activity; an ~70–90% increase in NBD-FFA over time was observed
(Figure 5A; n = 2–3). Notably, a very large increase in NBD-FFA in CV aliquots that were pre-incubated
with 104.0 µM [Ca2+]free confirmed Ca2+ promoted CV luminal PLA2 activity (Figure 5B, n = 3).
In contrast, 18.4 ± 2.0 picomoles NBD-PC was detected in buffer controls and no significant change
was detected even after 10 min incubation with the CV luminal protein (Figure 5A). This correlated
with no detection of NBD-FFA species in NBD-PC labelled CSC (n = 2 confirmatory experiments,
not shown). Thus, a decrease in NBD-PE and parallel increase in NBD-FFA over time and a large
increase in the generation of NBD-FFA in the presence of higher [Ca2+]free confirmed the presence of
a Ca2+ dependent catalytically active sPLA2 in the isolated CV luminal fraction, which is selective for
PE over PC.
The substrate preference of the ~63kDa CV membrane iPLA2 was also investigated by incubating
isolated CV membrane fragments with NBD-PE or -PC (Figure 6A; n = 2–3). Buffer without CV
membrane was used as the control to which the indicated amount of NBD-PC or -PE was added and
incubated for 10 min. In all incubations, no significant change in the NBD-labelled lipids nor generation
of NBD-FFA was observed. Therefore, to confirm whether the apparent membrane associated iPLA2
was lost or became inactive during CV membrane isolation, intact CV were assayed for PLA2 activity
following trypsin treatment and loss of iPLA2 was confirmed by western blotting. Loss of the ~63 kDa
iPLA2 protein band following trypsin treatment confirmed the presence of iPLA2 on the CV surface
(Figure 6B, n = 3; see also Figure S2). Both control and trypsin treated CV were then incubated with the
PLA2 selective substrate PED6—a glycerophosphoethanolamine with a BODIPY dye-labelled sn-2
acyl chain and a dinitrophenyl quencher-modified head group [79,80]. The cleavage of the BODIPY
dye from the sn-2 position by the action of PLA2 resulted in decreased quenching by the head group
which specifically indicated PLA2 activity. Relative to the 0 min control, there was no detectable PLA2
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activity in the trypsin treated CV, until 2 min. No significant change in the fluorescence intensity
between 2–30 min in trypsin treated CV, relative to 0 min, indicated a complete loss of iPLA2 activity
that correlated with loss of the iPLA2 band on the western blots (Figure 6C; n = 3). Absorbance
measurements of parallel samples confirmed that there was no major loss of CV over the course of
these incubations (not shown).Cell  2019, 8, 303 11 of 26 
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from the sn-2 position by the action of PLA2 resulted in decreased quenching by the head group which 
specifically indicated PLA2 activity. Relative to the 0 min control, there was no detectable PLA2 activity 
in the trypsin treated CV, until 2 min. No significant change in the fluorescence intensity between 2–30 
min in trypsin treated CV, relative to 0 min, indicated a complete loss of iPLA2 activity that correlated 
with loss of the iPLA2 band on the western blots (Figure 6C; n = 3). Absorbance measurements of parallel 
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Figure 6. (A) Time-dependent changes in NBD-PC and -PE, when incubated with CV membrane 
fragments (n = 2–3); (B) Western blot showing an apparent complete loss of iPLA2 in trypsin treated 
CV (n = 3). A total of 5µg CV membrane protein per lane was resolved; (C) Time-dependent changes 
in the CV surface PLA2 activity in the intact CV assessed using PLA2-selective substrate PED6 [79,80] 
(n = 3). The loss of the fluorescence signal is consistent with the loss of PLA2 from the CV surface 
following ablation with trypsin. Functional assays showing the effects of trypsin treatment on CV-CV 
Ca2+ activity curves [45]; (D) Standard fusion assay (n = 2); (E) CV settle fusion assay (n = 3). (p-value, 
*< 0.05, **<0.005 indicates difference relative to the control). Note: The lanes in B are grouped together 
from the same western blot following removal of intervening lanes. 
Considering the apparent complete loss of the ~63 kDa iPLA2 from the external membrane of 
intact CV following trypsin treatment and the corresponding loss of activity assessed using the 
Figure 6. (A) Time-dependent changes in NBD-PC and -PE, when incubated with CV membrane
fragments (n = 2–3); (B) Western blot showing an apparent complete loss of iPLA2 in trypsin treated
CV (n = 3). A total of 5µg CV membrane protein per lane was resolved; (C) Time-dependent changes in
the CV surface PLA2 activity in the intact CV assessed using PLA2-selective substrate PED6 [79,80]
(n = 3). The loss of the fluorescence signal is consistent with the loss of PLA2 from the CV surface
following ablation with trypsin. Functional assays showing the effects of trypsin treatment on CV-CV
Ca2+ activity curves [45]; (D) Standard fusion assay (n = 2); (E) CV settle fusion assay (n = 3). (p-value,
* < 0.05, ** < 0.005 indicates difference relative to the control). Note: The lanes in (B) are grouped
together from the same western blot following removal of intervening lanes.
Considering the apparent complete loss of the ~63 kDa iPLA2 from the external membrane
of intact CV following trypsin treatment and the corresponding loss of activity assessed using the
selective PED6 substrate (Figure 6B,C), we also tested these same batches of control and trypsin
treated CV for functional activity. Parallel standard and settle fusion assays were thus carried out
(Figure 6D,E, n = 2–3). In the standard assay, there was no significant change in the fusion extent
although Ca2+ sensitivity appeared right-shifted following trypsin treatment; however, the shift was
not significant relative to the untreated controls. Notably, in the settle assay used to assess docking and
priming [42,47,49–52,54], fusion extent was significantly decreased to 54.3 ± 7.2% following trypsin
treatment (Figure 6E; n = 3, (p < 0.004)).
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4.4. The Effect of PLA2 Activities on CV-CV Fusion
As in previous work, to enable a tight focus on the late steps of Ca2+ -triggered exocytosis, including
the fusion mechanism itself, without having to contend with the ‘background’ of the PM, high purity
CV preparations were used to further assess the potential influences of the endogenous CV-associated
PLA2 activities. Both the sPLA2 and iPLA2 were thus again targeted with selective inhibitors to better
assess their potential influence(s) on the late steps of regulated exocytosis (Figure 7A,B; n = 3–19).
The standard endpoint CV-CV fusion assays yielded a characteristic sigmoidal Ca2+ activity curve
with an EC50 of 44.8 ± 3.8 µM [Ca2+]free (Figure 7A; n = 19), which was translationally invariant with
CV-PM fusion (Figure 1; n = 14) [42,45,49,51]. A significant decrease in fusion extent to 95.3 ± 2.9% and
80.0 ± 10.7%, was observed in CV treated with 20 µM and 200 µM LY311727, respectively (Figure 7A).
Fusion of CV treated with 100 µM and 500 µM BEL were also reduced to 96.0 ± 3.2% and 90.0 ± 6.4%,
respectively (Figure 7A); following treatment with 50 µM and 200 µM FKGK-11 fusion extent was
reduced to 87.4 ± 8.5% and 75.4 ± 7.3%, respectively (Figure 7A). A significant right-shift in Ca2+
sensitivity, to yield EC50 of 78.9 ± 9.4 µM [Ca2+]free and 79.8 ± 7.5 µM [Ca2+]free was also observed
following treatment with 50 µM and 200 µM FKGK-11.
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Figure 7. Effects of LY311727 (selective for sPLA2) and BEL and FKGK-11 (both selective for iPLA2)
on CV-CV Ca2+ activity curves, fusion extent and Ca2+ sensitivity (EC50); (A) standard fusion assay,
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When tested in the settle assay, CV treated with all doses of the inhibitors showed further
decreases in fusion extent. These concentration-dependent decreases in fusion were to 89.9 ± 4.6% and
53.5 ± 13.4% in 20 µM and 200 µM LY311727 treated CV, respectively; 91.3 ± 4.6% and 87.6 ± 6.6% in
100 µM and 500 µM BEL treated CV, respectively; and 77.0 ± 16.0% and 58.9 ± 10.9% in 50 µM and
200 µM FKGK-11 treated CV, respectively, confirming the role(s) of PLA2 isozymes in promoting and
maintaining CV priming and/or docking (Figure 7B). To confirm that changes in the CV-CV fusion
parameters were associated with perturbed PLA2 activities, total lipid changes were assessed from
the same preparations following inhibitor treatments. Treating CV with LY311727, BEL and FKGK-11
caused significant concentration-dependent decreases in endogenous FFA levels, relative to a basal
FFA level of 15.7 ± 0.51 fmoles/µg MP (Figure 8; n = 3–4). FFA levels decreased to 12.9 ± 1.3 and
8.9 ± 3.5 fmoles/µg MP in CV treated with 20 µM and 200 µM LY311727, respectively. Additionally,
a significant increase in the endogenous PE levels in the CV treated with 200 µM LY311727 (Table 2),
confirmed the inhibitory action of LY311727 on PE-selective PLA2. Treating CV with 500 µM BEL
also significantly reduced FFA levels to 1.3 ± 6.7 fmoles/µg MP (Figure 8A,B; n = 4–12) and increased
TAG levels to 376.7 ± 22.5 picomoles/µg MP, relative to the basal level of 217.2 ± 40.9 picomoles in the
control (Figure S1B, n = 3–8; also seen in the BEL treated CSC, Figure S1A, n = 3–5).
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protocol was used to resolve the lipids [56].
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Table 2. Endogenous PE and PC levels in (A) CSC and (B) CV, treated with the indicated doses of the inhibitors. ND-not done; NA-not applicable.
A
PE (Picomoles/µg CSC
Membrane Protein) Mean SEM Student t-Test Sample Size (n)
PC (Picomoles/µg CSC
Membrane Protein) Mean SEM Student t-Test Sample Size (n)
Control 29.5 7.5 5 Control 47.7 11.0 6
LY311727 20 µM ND NA NA NA LY311727 20 µM 66.6 3.0 0.38 2
LY311727 200 µM ND NA NA NA LY311727 200 µM 38.9 2.2 0.68 2
BEL 100 µM ND NA NA NA BEL 100 µM ND ND NA NA
BEL 500 µM 28.0 7.5 0.90 3 BEL 500 µM 77.2 5.0 0.31 3
FKGK-11 50 µM 51.0 7.6 0.11 3 FKGK-11 50 µM 63.2 19.1 0.47 3
FKGK-11 200 µM 31.8 9.3 0.85 3 FKGK-11 200 µM 50.7 8.9 0.86 3
B
PE (Picomoles/µg CV
Membrane Protein) Mean SEM Student t-Test Sample Size (n)
PC (Picomoles/µg CV
Membrane Protein) Mean SEM Student t-Test Sample Size (n)
Control 46.0 5.5 11 Control 75.1 11.8 13
LY311727 20 µM ND NA NA NA LY311727 20 µM 96.4 26.3 0.5 3
LY311727 200 µM 70.5 5.1 0.05 3 LY311727 200 µM 114.2 19.9 0.1 6
BEL 100 µM ND NA NA 1 BEL 100 µM ND NA NA NA
BEL 500 µM 46.6 12.7 0.96 5 BEL 500 µM 57.3 7.2 0.4 5
FKGK-11 50 µM 40.4 12.9 0.66 3 FKGK-11 50 µM 53.5 26.0 0.4 3
FKGK-11 200 µM 22.5 6.7 0.06 3 FKGK-11 200 µM 42.4 16.5 0.2 3
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5. Discussion
Using bioinformatics and a top-down proteomic approach combined with lipid analyses of
isolated native CSC and CV, here we have identified endogenous, vesicle associated PLA2—a sPLA2 in
the CV lumen and an iPLA2 on the CV surface—and also demonstrated that their activities play a role
in promoting and maintaining the docked and/or primed state of secretory vesicles. The results are
consistent with previous findings in platelets that PLA2 activity is not essential for fusion per se but has
clear modulatory roles late in the exocytotic pathway [81].
5.1. PLA2 Activity and Their Effects on CSC Fusion
Initial assessments of CSC confirmed the existence of endogenous PLA2 activities and that these were
associated with the late steps of the regulated exocytotic pathway (Figures 1 and 2). Blockade of these
PLA2 activities using the well-characterized iPLA2 inhibitors, BEL [35,64,66,78] and FKGK-11 [35,67] and
the sPLA2 inhibitor LY311727 [68], caused significant decreases in endogenous FFA levels (Figure 1A)
and an increase in PE levels (Table 2). Importantly, a significant decrease in endogenous FFA but
increase in NBD-FFA in BEL treated CSC also indicated the presence of BEL sensitive as well as
insensitive PLA2 isozymes, the latter seemingly an sPLA2 (Figure 1A,B). Furthermore, to assess for
potential nonspecific inhibitory effects of BEL on other enzymes [78], unlabelled and NBD-PC labelled
CSC were treated with another iPLA2 inhibitor, FKGK-11. The significant concentration-dependent
increase in NBD-FFA (similar to that seen with BEL; Figure 1B) supported the interpretation that BEL
and FKGK-11 targeted at least one common molecular entity. This might also indicate that alternate
iPLA2 isoforms or proteoforms compensated for the loss, in the presence of BEL or FKGK-11. In contrast,
using LY311727 to block sPLA2 resulted in a concentration-dependent decrease in endogenous FFA
with no change in NBD-FFA, generated from NBD-PC labelled CSC (or NBD-PE labelled CSC; n = 1,
not shown). These data indicated an active sPLA2 that could not access the exogenous NBD-PE or -PC
(Figure 1A,B), despite the fact that NBD-PE was also seen to be a preferred substrate of CV luminal
PLA2 (Figure 5A). Also, no significant change in the fluorescence intensity in the 30 min control, relative
to the 0 min control (Figure 6C), indicated that 30 min was insufficient for any putative CV flippase to
translocate PED6 (a modified PE) toward the CV lumen; had there been such translocation of PED6,
a significant increase in fluorescence intensity should have occurred within 30 min due to luminal
sPLA2 activity.
Notably, a significant increase in TAG in the BEL treated unlabelled CSC provided an early
indication that iPLA2 could be the isozyme on CSC (Figure S1A and [34,64]). The proposed
‘housekeeping’ function of iPLA2 is to generate lyso-phospholipid acceptors for the incorporation of FFA
into membrane phospholipids [34,35,64,82]. Upon iPLA2 inhibition, lyso-phospholipid acceptor levels
decrease, consequently leading to an increase in FFA concentration [29,64]. Under such a condition,
the bulk of FFA is incorporated in the de novo metabolites TAG, DAG and MAG (Figure S1A,B) [64].
BEL also inhibits magnesium-dependent phosphatidate phosphohydrolase (PAP), an enzyme catalysing
the conversion of PA to DAG; however, there were no changes in PA in BEL treated CSC (Figure 1B).
Overall, the data suggested the presence of more than one catalytically active form of PLA2 on
CSC, some of which may be strategically localized to maintain the docked and release-ready state of
CV on the PM [29]. Blocking PLA2 activities using well characterized iPLA2 inhibitors (BEL [78] and
FKGK-11 [35,67]) and an sPLA2 inhibitor (LY311727 [68]) caused significant inhibition of CSC fusion
suggesting that even fully docked and fusion-ready CV are sensitive to changes in local PLA2 activity
(Figures 1B and 2).
5.2. Bioinformatics
With functional confirmation of the presence of active PLA2 species and association of their
metabolites with the late steps of Ca2+-triggered exocytosis, we used a combined bioinformatics and
top-down proteomics approach to identify and localize the active isoforms. Orthologs and paralogs are
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hypothesized to share high structural and functional similarity [83]; proteins essential to fundamental
molecular mechanisms have a similar structure and function from urchin to mammals [37,73,74,83].
Accordingly, there was substantial homology in amino acid sequence between urchin and mammalian
sPLA2 and iPLA2, particularly at the catalytic sites (Figure 3 and Table 1) [37]. The putative urchin
sPLA2 shares conserved catalytic and regulatory regions of >75% identity and similarity with the
mammalian orthologs (Table 1), including the highly conserved histidine and aspartic acid in the
catalytic site consensus sequence (HDCCY) and the histidine in the Ca2+ binding loop (HCGVGG)
(Figure 3A), at which LY311727 binds via its amide group [66]. Similarly, the iPLA2 share conserved
catalytic and regulatory domains, including the conserved active site serine in the GXSXG consensus
sequence that interacts with FKGK-11 [37,69] and the conserved cysteine residues are alkylated by the
active BEL metabolites [78]. The urchin iPLA2 thus shares conserved catalytic and regulatory domains
with the human and murine orthologs (Figure 3B and Table 1). Additionally, it also contains an ATP
binding consensus motif (GGGVKG) and a N-terminal caspase-3 cleavage site (DVTD), that are all
characteristic of iPLA2β (Figure 3) [35,84]. Notably, iPLA2β and sPLA2 genes are conserved in lower
eukaryotes, further indicating an essential role of these enzymes [37].
5.3. Top-Down Proteomics Identify CV Associated PLA2 Isozymes
Based on the bioinformatics we then carried out targeted top-down proteomic analyses using
2DE and immunoblotting. These analyses identified a highly conserved catalytically active ~14 kDa
CV luminal sPLA2 isozyme (Figure 4A) [25,26,36,85,86] having substrate preference for PE over PC
(Figure 5A,B) [26]. Indeed, there are other reports of 14 kDa sPLA2 species having a substrate selectivity
for PE over PC [17,87]. An increase in the activity of this CV luminal sPLA2 species in the presence of
[Ca2+]free was also confirmatory of its identification (Figure 5B) [25,27]. Similarly, using an antibody
to the human form, we detected an ~63 kDa iPLA2 on both CSC and CV membranes (Figure 4B,C),
although having different isoelectric points (pI). One of the most common post-translation modifications
(PTM) causing a shift in pI is phosphorylation, resulting in an increase in the net negative charge on
the protein. Hence, CV membrane iPLA2 isozymes with pI of ~5.2 and 5.4 may be phosphorylated
(or otherwise modified) species relative to the bulk of the enzyme found on CSC (pI of ~6.2) (Figure 4B,C);
the broad potential influence of protein phosphorylation on the late steps of exocytosis has been well
documented [52]. The ~63kDa iPLA2 is proposed to arise from the proteolytic cleavage of a nascent full
length 80–85 kDa iPLA2 [35,76,77]. Therefore, together with in-silico analysis (Figure 3B), identification
of an ~63 kDa iPLA2 on the CV membrane (Figure 4C) and the significant decrease in endogenous
FFA in BEL and FKGK-11 treated CV (Figure 8A,B) with a parallel increase in TAG (Figure S1B),
confirmed a catalytically active membrane bound CV iPLA2 [35,64,76,77,82]. Notably, on comparing
CSC and CV data (Figure 4B,C), it would seem that much more of the iPLA2 may be localized to the
PM, some (small) fraction presumably near or at sites of CV docking and fusion. The putative urchin
iPLA2 contains 57 potential trypsin cleavage sites, predicted by PeptideMass [88] and thus cleavage at
even a few of these sites would destroy the enzyme. Hence, loss of the 63 kDa CV iPLA2 following
trypsin treatment (Figure 6B) and associated decrease in signal from the PLA2 selective PED6 substrate
(Figure 6C), further confirmed the presence of an active iPLA2 on the external CV membrane. Thus,
proteolytic removal of CV surface proteins, including iPLA2, caused a significant decrease in fusion
extent to 54.3 ± 7.2% in the settle fusion assay that evaluates the priming and docking capacity of CV
(Figure 6E), indicating that vesicle surface proteins including iPLA2 and SNAREs [29,41–45,89]—and
possibly other as yet unidentified proteins—are critical for priming and/or docking. This is consistent
with a suggested link between the CV surface PLA2 activity and influences on the late steps of the
exocytotic pathway [29].
5.4. CV Associated PLA2 Isozymes Regulate Docking and/or Priming
Finally, we sought to test whether the identified PLA2 isozymes are components of the
minimal molecular machinery present on CV which enables docking, Ca2+ sensing and membrane
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merger [38,42,43,45,47–52,55,90–92]. Thus, CV were treated with selective PLA2 inhibitors and
changes in the fusion parameters were assessed using the well-established standard and settle
fusion assays [38,42,43,45,47–54,90–92]. Consistent with the significant concentration-dependent
decrease in fusion extent in CSC fusion assays, comparable effects were seen in the standard CV
fusion assay following treatments with LY311727, BEL and FKGK-11 (Figure 7A). However, a far
more pronounced decrease in the fusion extent in the settle assays (Figure 7B) confirmed that
CV associated PLA2 isozymes or their metabolites play a critical role in docking and/or priming.
The significant concentration-dependent decrease in endogenous CV FFA following the inhibitor
treatments (Figure 8A,B), significant increase in PE (Table 2; in CV treated with 200 µM LY311727) and
parallel increase in TAG (Figure S1B; in CV treated with 500 µM BEL) confirmed that these inhibitors
targeted CV associated PLA2 isozymes.
Furthermore, iPLA2 hydrolyse BEL to generate diffusible Bromomethyl Keto Acid (BMKA),
which alkylates cysteine thiols in iPLA2 causing its inhibition, in addition to non-specific alkylation
of cysteine thiols present in other proteins [78]. Therefore, the significant reduction in the Ca2+
sensitivity of CSC treated with 500 µM BEL (Figure 2), relative to a lack of effect on CV treated
identically (Figure 7A,B), suggested that BMKA acted (to some extent) like N-ethylmaleimide (NEM)
in CSC [90,92]. This indicates additional thiol sites on the PM that regulate efficiency of the fusion
mechanism (i.e., Ca2+ sensing). In terms of targeted inhibition, it should be noted that the compounds,
LY311727, BMKA and FKGK-11 are highly hydrophobic with log P values of 1.92 ± 0.62, 3.90 ± 0.37
and 5.40 ± 0.89, respectively, where the partition coefficient (P) = [organic]/[aqueous] (calculated
using ADC/ChemSketch [93]). Hence, these compounds have a high likelihood to intercalate into or
cross the CV membrane. Indeed, the significant concentration-dependent decrease in fusion extent
upon 200 µM LY311727 treatments, to 33.6 ± 20.8%, 80.0 ± 10.7% and 53.5 ± 13.4% in the CSC,
CV-CV standard and settle fusion assays, respectively, (Figure 2A,B and Figure 7A,B) and; the parallel
decrease in endogenous FFA (Figures 1A and 8A,B) indicated that inhibition of the CV luminal sPLA2
reduced CV priming and/or docking. Although BMKA and FKGK-11 may also have crossed the
CV membrane, it seems unlikely that these would inhibit the sPLA2—its sulfhydryl groups would
already be engaged in intra-molecular disulphide bonding and thus would not be susceptible to BMKA
induced alkylation [78] and the absence of a catalytic site serine would obviate FKGK-11 binding [67].
Therefore, overall, the inhibitors chosen are expected to be highly selective for the PLA2 species in
question and thus reflect selective influences on the functional assays.
5.5. Concluding Remarks
According to the Stalk-pore hypothesis, the fusion of two distinct membrane bilayers proceeds
through sequential steps resulting in the localized mixing of proximal monolayers followed by
fusion of the distal monolayers [94–97]. This enables vesicle content mixing (homotypic fusion) or
release (heterotypic fusion) and subsequent content dispersal. PLA2 activity produces both negative
and positive curvature lipids—LPC and FFA, respectively—which are known to inhibit or promote
fusion depending on their site of incorporation [10,11,29,94,95,98]. In this regard, localization of the
endogenous catalytically active PLA2 isozymes that supply LPC and FFA near the docking and/or
fusion site is of critical importance. The internal CV microenvironment has a pH of ~5.5 and contains
~100 mM calcium, mostly in a bound state, as has also been found in other (mammalian) secretory
vesicles [30,86,99–101]; however, the estimated global luminal [Ca2+]free is ~1–10 µM, occurring as
transients, linked in part to the opening of p-type Ca2+ channels [30]. As these are global measures,
the local [Ca2+]free at the CV membrane would be much higher. This is also consistent with the estimates
of luminal [Ca2+]free in chromaffin granules under basal conditions [100]. Hence, in response to CV
luminal Ca2+ transients in vivo, the activity of localized luminal sPLA2 would increase, preferentially
hydrolysing PE on the inner CV monolayer (Figures 4A and 5A,B ), at or immediately adjacent to
the docking/fusion site. Thus, under basal conditions, the external CV membrane associated iPLA2
generates LPC and FFA by cleaving PC on the outer CV monolayer, while luminal sPLA2 produces LPE
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and FFA on the inner CV monolayer. Such localization of iPLA2 on the outer vesicle (and inner plasma)
membrane, near docking/fusion sites, would block spontaneous merger of the vesicle and PM due to
high local levels of LPC at membrane contact sites, in particular considering the substantially higher
positive intrinsic curvature of LPC relative to LPE [98]. As such, this might act as a native fusion ‘brake’
that must be overcome by the Ca2+-triggered fusion mechanism [29], in which basal LPC production is
somewhat balanced by intermittent LPE production via transient sPLA2 activity (Figure 9). In this
regard and that of FFA (see below) it would also be important to assess the distribution of fatty acid
species at sn-1 and sn-2 of the endogenous CV membrane PC and PE. The net accumulation of FFA
on cis or trans monolayers and any associated effects would be dependent on the rate of passive
diffusion, flipping efficiency, rate of metabolism, site of incorporation, chain length and degree of
unsaturation [10,95,102–107]. Notably, perhaps complimentary to the actions of LPC and LPE, PLA2
derived FFA has been proposed to support the formation of trans SNARE complexes to maintain the
primed and/or docked state of vesicles [4,29,108,109]. Importantly, basal CV luminal sPLA2 activity
supported CV-PM and CV-CV fusion (Figure 2, Figure 6D,E and Figure 7A,B); whether the activity
is also sensitive to transient changes in luminal [Ca2+]free and how these may be linked to the final
membrane merger steps are unknown. However, the likely coordinated action (i.e., cross-talk) of
the CV luminal sPLA2 and outer membrane bound iPLA2 in maintaining the docked, fusion-ready
state of vesicles on the PM is evident as both interventions used here—pharmacological inhibition of
CV luminal sPLA2 and membrane associated iPLA2 and proteolytic removal of iPLA2—significantly
impaired priming and/or docking.Cells 2019, 8, 303 20 of 26 
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6. Conclusions
The data confirm (i) the presence of endogenous, catalytically active CV associated PLA2
isozymes—a CV luminal sPLA2 and an iPLA2 associated with the outer CV membrane; and (ii) that
proteolytic removal of CV surface proteins including iPLA2 or the pharmacological inhibition of both the
isozymes significantly reduces priming and/or docking. Based on this as well as previously measured
vesicular Ca2+ transients, basal Ca2+ dependent CV luminal sPLA2 activity and CV membrane
attached iPLA2 would appear to act together to support efficient vesicle priming and/or docking.
While intriguing, this warrants further study, particularly relating to the apparent effects of FFA on the
formation of SNARE complexes and/or in modulating membrane biophysical properties, as FFA is also
known to induce the transition from the bilayer to the hexagonal phase upon its incorporation in the
membrane [10,107,110].
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Figure S2: (A) SDS-PAGE of total CV membrane protein isolated from trypsin treated CV and the parallel untreated
control; (B) secondary antibody control western blot to identify non-specific protein binding. A total of 5 µg CV
membrane protein per lane was resolved.
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The canonical Phospholipase A2 (PLA2) metabolites lysophosphatidylcholine (LPC) and arachidonic acid
(ARA) affect regulated exocytosis in a wide variety of cells and are proposed to directly influence
membrane merger owing to their respective spontaneous curvatures. According to the Stalk-pore hy-
pothesis, negative curvature ARA inhibits and promotes bilayer merger upon introduction into the distal
or proximal monolayers, respectively; in contrast, with positive curvature, LPC has the opposite effects.
Using fully primed, release-ready native cortical secretory vesicles (CV), well-established fusion assays
and standardized lipid analyses, we show that exogenous ARA and LPC, as well as their non-
metabolizable analogous, ETYA and ET-18-OCH3, inhibit the docking/priming and membrane merger
steps, respectively, of regulated exocytosis.
© 2019 Elsevier Inc. All rights reserved.1. Introduction
Membranemerger and fusion pore opening are the final steps in
regulated exocytosis enabling the release of vesicular content into
the extracellular space. Prior to this merger, vesicles must attach to
the plasma membrane (PM) and undergo a series of molecular
reactions to become fully docked, primed and release-ready,
including formation of trans SNARE (soluble NSF attachment pro-
tein receptor; NSF, N-ethylmaleimide-sensitive factor) complexes.
The proposed functions of SNARE complexes include docking and
priming [1e5], and membrane fusion [3,5] (but also see Ref. [5] for
other proposed functions); the latter is suggested to be driven by
NH2 terminus-to-COOH terminus ‘zippering’ of the parallel coiled-
coil SNARE domains, that are proposed to pull adjacent membranes
together [3], purportedly with sufficient energy to overcome
intermembrane repulsive forces [3,5,6]. Yet, at native densities, in
native membranes, such SNARE interactions alone do not ‘drive’
fusion [1,6e9]; indeed, complete ablation of SNAREs did not block3, 1-O-octadecyl-2-Omethyl-
etraynoic Acid; LPC,
abral), jcoorssen@brocku.ca
oorssen, Arachidonic acid an
earch Communications, httpsCa2þ-triggered fusion, implicating critical role(s) of other proteins
and lipids in membrane merger and other late steps of exocytosis
[1,2,10e12]. The trans SNARE interactions are said to initiate once
membranes are ~8 nm apart, and zippering continues until mem-
branes are ~2e4 nm apart, bringing adjacent membrane bilayers
into their closest estimated proximity [13,14]. Although in close
apposition (~3e8 nm, predicted by course-grain models; [13]),
membranes still do notmerge spontaneously due, at least in part, to
intermembrane repulsive forces [14,15]. This may yield apposing
contact sites that are (almost) purely lipidic. Furthermore,
decreasing lysophosphatidylethanolamine (LPE), in the distal
monolayers of contacting vesicles reduces docking/priming [12],
consistent with a reduced fusion of dense core vesicles (DCV) to
SNARE containing bilayers that have higher phosphatidylethanol-
amine (PE) in the distal monolayer [16]. Also, it is well known that
lysophosphatidylcholine (LPC) in the proximal monolayers inhibits
membrane merger [17e19]. In this regard, optimum levels and a
critical balance between LPE and LPC on the distal and proximal
monolayers of the apposed bilayers, respectively, at or near fusion
sites, together seem to serve as a molecular brake to block ‘spon-
taneous’ membrane merger in an unstimulated state [11,12].
Nevertheless, upon Ca2þ triggering, membranes at the fusion site
quickly merge, resulting in content release [20e22]. These fusion
sites in native membranes are rich in cholesterol and sphingo-
myelin, that together organize microdomains that ensure fusiond lysophosphatidylcholine inhibit multiple late steps of regulated
://doi.org/10.1016/j.bbrc.2019.05.106
D. Dabral, J.R. Coorssen / Biochemical and Biophysical Research Communications xxx (xxxx) xxx2efficiency (e.g., Ca2þ sensing, docking/priming) [4,22e24]. Addi-
tionally, cholesterol acts as a key local contributor of negative
curvature for progression to the hemifusion stage [4,22,25], while
optimal levels of sphingolipids contribute to both the efficiency and
capacity for fusion [23,26]. Other Ca2þ binding sites and effectors
that may be localized at the fusion site as ‘efficiency’ factors include
PS, cholesterol sulfate, and synaptotagmin [4,23,26,27].
Apart from modifying membrane biophysical properties, exog-
enous lipids, including (arachidonic acid; ARA) and LPC, alter
protein-protein interactions [28e31], membrane enzyme activities
[32,33] and membrane lipid homeostasis [11,32,34,35]. ARA en-
hances SNARE complex formation in vitro by acting on the regula-
tory Munc18, thus releasing syntaxin from Munc18/syntaxin
complexes [30]. However, considering the high flip-flop rate of ARA
(t1/2 of seconds) [3, 50, 51], lateral movement [51, 52], rate of pas-
sive diffusion [53], conversion to other membrane lipid species
[46,47] and its downstream metabolism to generate eicosanoids, it
remains uncertain that ARAwould be the active species to enhance
trans SNARE complex formation in vivo. Importantly, native mem-
branes contain enzymes that maintain lipid homeostasis [11,12,26],
therefore, to tightly couple functional and molecular analyses, a
quantitative assessment of the fate of exogenous lipids is always
necessary [12,22,26,36].
Here we assessed the effects of the canonical PLA2 metabolites,
ARA and LPC, on the late steps of Ca2þ triggered native membrane
fusion; their metabolic fate and functional contributions were
confirmed by the parallel use of non-metabolizable analogous
(Fig. 1).
2. Materials and methods
Reference lipids and oleoyl-LPC were from Avanti Polar Lipids
(Alabaster, AL, USA). Arachidonic acid (20:4) was from Matreya
LLC (Pennsylvania, USA). 1-O-octadecyl-2-Omethyl-rac-glycero-3-
phosphocholine (ET-18-OCH3) and Eicosatetraynoic Acid (ETYA)
were from Cayman Chemical (Ann Arbor, USA). Silica G-60 High-
Performance Thin Layer Chromatography (HPTLC) plates wereFig. 1. Structures of (A) ARA and ETY
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components, and organic solvents were of at least analytical grade.
All glassware used during lipid isolation was silanized (SigmaCote;
Darmstadt, Germany). The dried samples were stored in silanized
glass vials from Thermo Fisher Scientific (Oregon, USA).
CV treatment and Fusion assays: Native brown sea urchins
(Heliocedaris tuberculata) were maintained at ~7 - 8 C in the in-
house aquatic facility [12]. CV were isolated from unfertilized
eggs using a standardized protocol and suspended in Baseline
Intracellular Medium, (BIM, 210mM potassium glutamate, 500mM
glycine, 10mMNaCl, 10mM PIPES, 50 mM CaCl2, 1mMMgCl2, 1mM
EGTA, pH 6.7) supplemented with 2.5mM ATP, 2mM DTT and
protease inhibitors [1,2,10,12,22,25,36]. CV suspensions (OD
0.9± 0.05; n¼ 10) were treated with indicated concentrations of
ARA, ETYA, LPC and ET-18-OCH3 for 10min at 25 C and diluted
with 3e5 vol of ice-cold BIM, pH 6.7 immediately after incubation.
Stock solutions of LPC and ARA were prepared in ethanol and
delivered to CV suspensions to a final solvent concentration <0.1%
[25]. ET-18-OCH3 and ETYA were dissolved in BIM (pH 6.7) and
dimethyl sulfoxide, respectively; ETYA was delivered to a final
solvent concentration <1% [12,22,25]. LPC and ET-18-OCH3 con-
centrations were selected based on previous work [10,37]; ARA and
ETYA concentrations were selected based on considerations pro-
vided in Refs. [11,38]. CV fusion indicated by decrease in optical
density (OD) was measured using a POLARstar Omega microplate
reader (BMG Labtech, Offenburg, Germany). The final free Ca2þ
concentration ([Ca2þ]free) in parallel mock samples was measured
with a Ca2þ sensitive electrode (Calcium Combination ISE, EDT di-
rectION Limited) [12,26]. Standard and ‘settle’ fusion assays were
carried out as previously described [1,2,10,12,22,23,25,26,36]. Ali-
quots of CV suspension were snap frozen in liquid N2 and stored
at 80 C for later molecular analyses.
Lipid normalization and analyses: Membrane protein was
isolated in parallel with the total lipids, from the same CV aliquot, as
described previously [12]. Briefly, CV were lysed for 90 s and
isotonicity of the suspension immediately restored [12]. Mem-
branes were recovered by centrifuging at 125,000g, 4 C, for 3 hA and; (B) LPC and ET-18-OCH3.
d lysophosphatidylcholine inhibit multiple late steps of regulated
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resulting membrane pellet was solubilized in two-dimensional gel
electrophoresis (2DE) buffer [39]. Protein quantification was via a
solid-phase fluorescence-based assay using EZQ™ reagent from
Invitrogen (Carlsbad, CA) [12]. Total CV lipids were extracted ac-
cording to Bligh and Dyer, with established modifications
[12,22,25,40,41]. Lipid corresponding to 1 mg and 2 mg of total
membrane protein were assessed for neutral and phospholipids,
respectively [12,40]. Activation of silica plates was by wetting with
CH3OH:ethyl acetate (6:4) using the AMD 2 multi-development
unit (Muttenz, Switzerland) and subsequent heating at 110 C for
30min [12,22,25,40]. To resolve lipids, dried samples were dis-
solved in CHCl3:CH3OH (2:1 v/v) and loaded onto activated HPTLC
plates using the CAMAG automated TLC Sampler (Muttenz,
Switzerland). Neutral and phospholipids were resolved according
to established methods [22,25,36,40] and visualized on-plate at
460 nm/605 nm (Ex/Em) using the ImageQuant™ LAS 4000 Bio-
molecular Imager (GE Healthcare, Buckinghamshire, UK) [12,40].
Images were analyzed using MultiGauge v 3.0 (Fuji Photo Film Co.,
Ltd. Tokyo, Japan). Lipids of interest were quantified via calibration
curves of the appropriate standards, resolved in parallel with the
sample lipids.
2.1. Data analysis
All conditions were tested in quadruplicate, and experiments
replicated as indicated (n). Data were normalized by setting zero %
fusion at <0.3 mM [Ca2þ]free and 100% fusion at >100 mM [Ca2þ]free.
Ca2þ activity curves were fit using a sigmoidal 4-parameter logistic
model (PRISM 7.03; GraphPad, San Diego, US). Data are reported as
mean± SEM. Two-sample, two-tailed t-tests with P< 0.05 were
considered significant.
3. Results and discussion
Using stage-specific, release-ready CV isolated from unfertilized
sea urchin eggs, well-established fusion assays, and standardized
lipid analyses [1,2,4,10,12,23,25,26,36,40], exogenous ARA and LPC
are shown to inhibit vesicle docking/priming and membrane
merger, respectively. This was further confirmed by their respective
non-metabolizable analogues, ET-18-OCH3 and ETYA (Fig. 1).
ARA and LPC are ubiquitous, and small amounts of these me-
tabolites are produced in vivo at any instant by endogenous PLA2
[11,38]; limited enzyme activity also occurs in the CV membrane,
maintaining FFA levels at ~15 fmol/mg MP in an unstimulated state
[12]. Complexity arises due to various cellular PLA2 isozymes [42],
the high flipping rate of ARA [11,43,44], and the fact that both
lysophospholipids and FFA promote as well as inhibit membrane
merger based on their site of incorporation [11,18e20], thus posing
challenges to dissect their specific roles in regulated exocytosis.
Hence, high purity CV preparations lacking cytosolic components
but retaining the minimal machinery necessary for Ca2þ sensing,
docking/priming, and fusion [1,2,4,10,12,25,26,36], are exceptional
models with which to dissect the role(s) of PLA2 metabolites in the
late stages of regulated exocytosis.
3.1. Effects of exogenous ARA and ETYA on fusion and their
metabolic fate
Triggering CV with increasing [Ca2þ]free yielded a characteristic
sigmoidal Ca2þ activity curve with an EC50 of 55.6± 3.8 mM
[Ca2þ]free (Fig. 2A; n¼ 5) [1,10,12,22,36]. Treating CV with 85 nM
ARA or 85 nM ETYA, significantly reduced fusion to 59.8± 13.1% and
19.7± 5.0%, respectively, but only in the settle fusion assay (Fig. 2;
n¼ 2e3). The significant decrease in fusion extent in ARA treatedPlease cite this article as: D. Dabral, J.R. Coorssen, Arachidonic acid an
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(FFA) (Fig. 2C; n¼ 4), confirming incorporation of the exogenous
ARA into the CV membrane. There were no significant changes in
other neutral (Fig. 2C, representative chromatogram) and phos-
pholipid species (not shown). The basal endogenous FFA in un-
treated controls was 14.9± 2.0 fmol/mg CV membrane protein
(fmol/mg MP) (Fig. 2C; n¼ 4), consistent with previous measures
[12]. The ~22% increase in endogenous FFA to 18.4± 0.7 fmol/mg MP
was significant in the ARA treated CV, relative to 14.3± 0.7 fmol/mg
MP in the ETYA treated CV, confirming that ETYA was not metab-
olized (Fig. 2C; n¼ 4). No significant change in Ca2þ sensitivity was
observed in either of these treatments (Fig. 2).
ARA maintained optimum fusion (i.e., 100± 1.3%) in the stan-
dard assay (Fig. 2A; n¼ 3e5), and thus did not interfere with the
fundamental ability of CV to fuse. That ARA can rapidly diffuse
across the membrane [38] and also be rapidly metabolized [34,35],
suggested that (exogenous) ARA could directly alter membrane
biophysical properties owing to its negative spontaneous curvature
or exert an indirect effect by generating ‘active’ downstream me-
tabolite(s). To dissociate these potential effects, a metabolically
stable analogue, ETYA, having four alkyne bonds, in contrast to
alkene bonds in ARA, was used (Fig. 1A). ETYA also had no effect on
fusion extent in the standard assay, confirming that neither ARA
nor its analogue had a direct effect on fusion. However, in the settle
assay, fusion was reduced to ~40% and ~20% in ARA and ETYA
treated CV, respectively, confirming that ARA and ETYA selectively
impaired docking/priming (Fig. 2A and B). Furthermore, an ~20%
increase in endogenous FFA in ARA treated CV, indicated conver-
sion of exogenous ARA into endogenous FFA, while no such change
was seen in ETYA treated CV (Fig. 2C). Hence, membrane incorpo-
rated ETYA most likely acted directly to reduce docking/priming by
~80%, suggesting that ARA also acted comparably, at least until
metabolized. It is well-known that incorporation of ARA into the
distal monolayers of contacting bilayers directly inhibits membrane
merger owing to its negative spontaneous curvature [17,18,20].
Therefore, it seems likely that ARA (and potentially ETYA) equili-
brated between the monolayers of the CV membrane, negating
specific curvature effects but perhaps overwhelming the basal
balance of FFA necessary to promote andmaintain docking/priming
under basal conditions [11].
3.2. Effects of exogenous LPC and ET-18-OCH3 on fusion and their
metabolic fate
Treating CV with 100 mM LPC or 100 mM ET-18-OCH3, signifi-
cantly reduced fusion to 33.0± 5.6% and 26.3± 13.2% respectively,
in the standard fusion assay (Fig. 3A; n¼ 3e6). However, in the
settle fusion assay, fusion was further reduced to 24.0± 5.4% and
3.0± 2.9%, respectively, in aliquots of the same treated CV (Fig. 3B;
n¼ 3e6). Additionally, treating CV with 100 mM ET-18-OCH3
reduced Ca2þ sensitivity causing a significant rightward shift in
EC50 to 171.0± 53.4 mM [Ca2þ]free, relative to the control EC50 of
65.7± 8.5 mM [Ca2þ]free in the standard fusion assay (Fig. 3A);
fusion was abolished in the settle assay following incorporation of
ET-18-OCH3 (Fig. 3B). Notably, an ~30% increase in endogenous PC
to 41.0± 1.9 pmol/mg MP was significant in the LPC treated CV,
relative to 30.4± 2.9 pmol/mg MP in the control (Fig. 3C; n¼ 5e8);
there was no significant change in PC levels in ET-18-OCH3 treated
CV. No significant changes were detected for any other phospho-
lipids (not shown).
Since 100 mM LPC reduced fusion by ~70% in both the standard
and settle fusion assays (Fig. 3A and B), it is essential to differentiate
whether this occurred due to blockade of membrane merger
[10,18,37] or reflected reduced docking/priming. The significant
decrease in fusion extent even after establishingmembrane contactd lysophosphatidylcholine inhibit multiple late steps of regulated
://doi.org/10.1016/j.bbrc.2019.05.106
Fig. 2. Effects of 85 nM ARA and ETYA on CV-CV fusion. Changes in the Ca2þ activity curves, fusion extent and Ca2þ sensitivity (EC50); (A) standard fusion assay (n¼ 3e5); (B) CV
settle fusion assay (n¼ 2e3) and; (C) the changes in endogenous FFA following treatment with indicated concentrations of ARA and ETYA, with a representative chromatogram;
n ¼ 4 separate experiments. (** ¼ 0.009; **** < 0.0001 represent significant differences from control; *<0.05 represent significant difference as indicated). Red arrow indicates
exogenous ARA and ETYA. The total lipid load in each lane corresponds to 1 mg CV membrane protein. (For interpretation of the references to colour in this figure legend, the reader
is referred to the Web version of this article.)
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brane merger, as has been well documented [18e20,37]. Also, an
~30% increase in endogenous PC indicated the conversion of
exogenous LPC in the CV membrane (Fig. 3C). Importantly, PC
essentially has zero intrinsic curvature, thus forming flat lamellar La
phases [17,45], and the flip-flop rates of PC and LPC in native
membranes are in the range of hours [44,46]. Therefore, exogenous
LPC as well as the small amounts of PC produced from it likely
accumulated in the outer CV monolayer. Nonetheless, with such
bulk lipid supplementation, it is clear that complex nonspecific
effects on native membranes are likely to occur, necessitating
additional assessments to confirm functional contributions of these
lipids. Thus, as above, treating CV with a non-metabolizable
analogue, 100 mM ET-18-OCH3, reduced fusion to a comparable
extent in the standard fusion assay, but completely blocked fusion
in the settle assay, likely due to the consistent presence of the
analogue (Fig. 3B). Nonetheless, decreased Ca2þ sensitivity in thePlease cite this article as: D. Dabral, J.R. Coorssen, Arachidonic acid an
exocytosis, Biochemical and Biophysical Research Communications, httpstandard fusion assay with ET-18-OCH3 treated CV also indicated
an effect on fusion efficiency, which has been linked to disruption of
critical local microdomains [23,24,26]. Thus, one must consider the
structural differences between LPC and ET-18-OCH3 that include
replacement of a hydroxyl group (OH) in LPC with a methoxy group
(OCH3), and addition of a carbonyl group (C]O) on the fatty acid
(Fig.1B). The absence of OH in ET-18-OCH3 precludes the possibility
of hydrogen bonding with the membrane phospholipids [47,48]
and thus may contribute to the select decrease in Ca2þ sensitivity
(Fig. 3A). In this regard, it is notable that ET-18-OCH3 is known to
destabilize membrane domain structures by competing with
sphingomyelin to interact with cholesterol [49] and forms fewer
and smaller microdomains in monolayers of complex lipid extracts
in vivo [50]. Therefore, it seems that ET-18-OCH3 additionally dis-
rupted microdomains defining fusion sites to an extent sufficient to
reduce the efficiency (i.e., Ca2þ sensitivity) of the mechanism
[23,24,26,49]. As ET-18-OCH3 was a more potent inhibitor of fusiond lysophosphatidylcholine inhibit multiple late steps of regulated
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Fig. 3. Effects of 100 mM LPC and ET-18-OCH3 on CV-CV fusion. Changes in the Ca2þ activity curves, fusion extent and Ca2þ sensitivity (EC50); (A) Standard fusion assay (n¼ 3e6);
(B) CV settle fusion assay (n¼ 3e6) and; (C) the changes in endogenous PC following treatment with indicated concentrations of LPC and ET-18-OCH3, n ¼ 3 separate experiments.
(* < 0.05; **** < 0.0001 represent significant differences from control). Red arrows indicate exogenous LPC and ET-18-OCH3. Note: The apparent difference in the intensity of lipid
species between the two chromatograms is due to the necessity for different exposures during image capture. The total lipid load in each lane corresponds to 2 mg CV membrane
protein. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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the inhibitory process except perhaps to limit the effects by
reducing the amount of exogenous LPC. Indeed, local production of
PC may have contributed to the stabilization of critical micro-
domains, consistent with a lack of influence of the LPC treatment on
Ca2þ sensitivity (Fig. 3A and B).
Thus, the data indicate that exogenous LPC and ET-18-OCH3 in
the proximal monolayers of contacting CV block membrane merger
due to their positive spontaneous curvature; the metabolic stability
of ET-18-OCH3 and its likely disruption of microdomains thus
resulted in a complete inhibition of fusion (Fig. 3). As the docked/
primed state of release-ready CV is maintained by the basal activ-
ities of CV surface iPLA2 that preferentially generate LPC in the
outer CV monolayer, it acts as a molecular ‘fusion brake’ to ensure
efficient maintenance of docking/priming prior to the triggering of
fusion [11,12] (Fig. 4A and B); here, exogenous LPC in the proximal
monolayer likely augmented the effects of the existing endogenousPlease cite this article as: D. Dabral, J.R. Coorssen, Arachidonic acid an
exocytosis, Biochemical and Biophysical Research Communications, httpsfusion brake owing to its added positive spontaneous curvature
[11] (Figs. 3 and 4C). In contrast, exogenous ARA, likely equilibrated
between the CV monolayers [38,43,44] upsetting the balance of
native FFA and thereby caused a nonspecific inhibition of docking/
priming (Figs. 2 and 4D). Furthermore, as in vitro experiments have
suggested that ARA promotes SNARE complex formation yet the
data here indicate blockade of docking/priming, it seems unlikely
that ARA itself performs such a function in native membranes.
4. Conclusion
Exogenous ARA selectively inhibits docking/priming but does
not have a direct role in membrane merger. In contrast, exogenous
LPC, in the proximal monolayers, blocked membrane merger,
consistent with previous studies. These outcomes were confirmed
by using the non-metabolizable analogues, ETYA and ET-18-OCH3.
The data also highlight the importance of transbilayer balance ofd lysophosphatidylcholine inhibit multiple late steps of regulated
://doi.org/10.1016/j.bbrc.2019.05.106
Fig. 4. Effects of exogenous LPC and ARA on late steps of native Ca2þ triggered fusion. (A) Non-contacting vesicles (B) Contacting vesicles with optimum levels of endogenous LPC
and FFA undergo fusion upon Ca2þ triggering (C) Contacting vesicles with exogenous LPC incorporated in the proximal monolayers, increasing potency of the endogenous fusion
‘clamp’ and (D) Exogenous ARA equilibrates in the bilayers of the contacting vesicle, reducing docking and/or priming.
D. Dabral, J.R. Coorssen / Biochemical and Biophysical Research Communications xxx (xxxx) xxx6lipid species in nativemolecular mechanisms, as well as the need to
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CHAPTER – 4 
 
Phospholipase A2 activating peptide disturbs native membrane lipid homeostasis, 
affecting terminal steps of Ca2+ triggered exocytosis 























Abstract: Melittin activates sPLA2 [1-4] and forms membrane pores, promoting regulated 
exocytosis [3,5-7]. Using CSC (cell surface complexes) and fully primed release-ready native 
cortical secretory vesicles (CV) isolated from unfertilized sea urchin eggs, here Phospholipase 
A2 activating peptide (PLAP) is shown to reduce endogenous free fatty acid (FFA) levels, 
increase phosphatidylethanolamine (PE), and inhibit priming/docking steps. This indicates that 
PLAP altered native lipid homeostasis and impaired priming/docking steps, while CV 
associated phospholipase D (PLD) and calcium-independent phospholipase A2 (iPLA2) 
activities were unaffected. Notably, PLAP also reduced membrane capacitance and the readily 
releasable pool (RRP) size in chromaffin cells. Overall, studies using well-established model 
systems – CSC and CV fusion assays, that enable tight coupling of functional and molecular 
analyses [8,11-17] and membrane capacitance measurement of chromaffin cells [18-20] - 






Sea urchin eggs and mammalian chromaffin cells carry out the different physiological function, 
however, in response to increasing [Ca2+]free yield a characteristic sigmoidal dose-response 
curve [11-13,15-17,21-28]. The exact role(s) of Ca2+ during triggering are as yet unclear. 
Nevertheless, studies suggest that Ca2+ may clear trans SNARE complexes to allow fusion 
[13,22,23,29] and induce conformational changes in the putative Ca2+ sensor - synaptotagmin 
[30]. The binding of Ca2+ to synaptotagmin is proposed to release its inhibitory effect on 
membrane merger that occurs due to unfavourable membrane bending [30]. Unfertilized sea 





trafficking stage(s), cortical secretory vesicles (CV) are translocated to the plasma membrane 
(PM) where they remain fully primed and release-ready until fertilization. Necessary docking 
and priming involve, at least in part, formation of trans SNARE complexes [13,15,23,32,33]. 
Therefore, unfertilized sea urchin eggs contain a single CV population at the cortex, compared 
to at least three distinct secretory vesicle pools near the PM in a chromaffin cell, termed the (i) 
unprimed pool (UPP); (ii) slowly releasable pool (SRP) and; (iii) readily releasable pool (RRP) 
[25,34,35]. Those docked vesicles that are fully primed and highly Ca2+ sensitive constitute the 
RRP and their distinct molecular state, is due to mechanisms that occur during their transition 
from the UPP to the RRP [36]. Such mechanisms involve the combined actions of calcium-
dependent activator protein for secretion - 1 and -2 (CAPS-1 and -2) [35,37-39] and 
mammalian uncoordinated (munc) [35,40]. Nevertheless, the close proximity of RRP to Ca2+ 
channels on the PM may also contribute to their high Ca2+ sensitivity [41,42]. Importantly, 
functional SNAREs maintain the RRP [43,44], as SNAP 25 deletion [23,36,45], blocking 
SNARE complex formation using antibodies [44] and their cleavage using Botulinum 
Neurotoxin A [46], significantly reduced RRP size [47,48]. Therefore, the molecular state of 
RRP in chromaffin cells is, in essence, analogous to the endogenously docked CV on the PM 
(CSC; cell surface complexes) in an unfertilized sea urchin egg. This is because both vesicle 
types are fully primed, morphologically docked at the PM utilizing already formed SNARE 
complexes and immediately undergo membrane merger in response to Ca2+ triggering 
[8,9,11,12,14,17,22-24,27,36,49-51]. 
Phospholipase A2 generates free fatty acids (FFA) and lysophospholipids (LPL) that 
modulate priming/docking and the membrane merger steps of regulated exocytosis, 
respectively [9,10]. Therefore, to enhance PLA2 activity [9], melittin homologous polypeptide, 
phospholipase A2 activating peptide (PLAP) was used, that has been seen to activate sPLA2 in 





characterized by leucine separated by six residues in the sequence KVLTTGXPPLI (Fig. 1A) 
[52]. Therefore, both have a tendency to form homo or heterodimers. Melittin monomers also 
have the ability to adopt a helical conformation that orients parallel to the membrane bilayer 
[53,54]. Therefore, it may also interact with SNARE complexes (Fig. 1A) to inhibit SNARE 
‘zippering’. Additionally, melittin is also suggested to form membrane pores, hence promote 
regulated exocytosis [3,5-7]. Also, melittin inhibits PKC [55,56], calmodulin-sensitive Ca2+ 
dependent protein kinase [56,57], phosphorylase kinase [58], and kappa kinases [59], and 
promotes secretory phospholipase A2 (sPLA2) [2,3,6,60-62], PM associated scramblase [63] 
and phospholipase D (PLD) activities [64]. Among these, PKC phosphorylates SNAP 25 
[47,48,65-67], PLA2 isozymes, and PLD regulates priming/docking [9,68] in the late steps of 
regulated exocytosis.  
Using well-established CV-PM and CV-CV fusion assays and standardized lipid 
analyses [8,9,11,13,15,17,23,24,68-69], PLAP is shown to inhibit fusion of endogenously 
docked CV with the PM. This occurs due to impaired molecular reactions associated with 
priming/docking. As PLAP reduced endogenous FFA and caused a parallel increase in 
endogenous PE, indicated that a critical level of endogenous lipids maintains priming/docking 
steps. Furthermore, PLAP caused no change in CV associated PLD and PLA2 activities, nor 
formed pores in native membranes as suggested in other studies [3, 5-7, 9,16]. Notably, a 
significant decrease in overall secretion and RRP size in PLAP (and LY311727) treated 
chromaffin cells, confirmed that PLAP altered common underlying molecular reactions 
associated with the priming/docking steps of regulated exocytosis. 
2. Materials and Methods 





Native sea urchins (Heliocedaris tuberculata) were maintained at 7-8 °C in the local aquatic 
facility ([9,10]). CSC and CV were isolated as previously described [8,13-15,22] and 
suspended in baseline intracellular medium (BIM, 210 mM potassium glutamate, 500 mM 
glycine, 10 mM NaCl, 10 mM PIPES, 50 μM CaCl2, 1 mM MgCl2, 1 mM EGTA pH 6.7) 
supplemented with 2.5 mM ATP, 2 mM DTT and 1X protease inhibitors [8,14]. PLAP and 
1,1,1,2,2-Pentafluoro-7-phenyl-3-heptanone (FKGK-11) were from Enzo Life Sciences 
(Farmingdale, NY) and Cayman Chemicals (Ann Arbor, US), respectively, and 3-(3-
acetamide-1-benzyl-2-ethylindolyl-5-oxy) propane sulfonic acid (LY311727) and Bromoenol 
lactone (BEL) were from Sigma Aldrich (St. Louis, US). The changes in optical density (OD) 
used to assess CV-PM and CV-CV fusion were measured using a POLARstar Omega 
microplate reader (BMG Labtech, Offenburg, Germany) [9,10,12,17]. Each treatment was 
tested in quadruplicate and repeated in separate experiments, as indicated (n). 
2.2 Lipid extraction, normalization and High-Performance Thin Layer Chromatography 
(HPTLC) 
Total CSC or CV lipids and parallel membrane proteins were extracted as previously described 
[8-10,14,68,70]). The dried lipid samples were dissolved in CHCl3:CH3OH (2:1; v/v) and 
loaded onto pre-conditioned silica gel 60 HPTLC plates [8-10,14,68]. For consistency and 
optimum detection of the individual lipid species, samples corresponding to 1 µg and 2 µg of 
membrane protein were used to resolve neutral and phospholipids, respectively [8-10], 
according to established methods [8,11,14,16]. The resolved lipids were visualized on-plate by 
heating plates that were homogeneously wetted with 10 % cupric sulfate in 8 % aqueous 
phosphoric acid at 145°C for 10 min [8,9]. Lipids of interest were quantified via calibration 
curves of the appropriate standards, resolved in parallel with the sample lipids. Images were 





(GE Healthcare, Buckinghamshire, UK) and analyzed using MultiGauge v 3.0 (Fuji Photo Film 
Co., Ltd. Tokyo, Japan). All lipids except arachidonic acid (ARA; 20:4) were from Avanti 
Polar Lipids (Alabaster, AL). ARA was purchased from Matreya LLC (Pennsylvania, US).  
2.3 PLD activity assay 
CV associated PLD activity was measured using an Amplex Red PLD assay kit (Invitrogen, 
Eugene, OR) with minor modifications [16]. Briefly, CV suspension in 1 X BIM, pH 6.5 
(supplemented with 2.5 mM ATP and 1X protease inhibitors [8,14]) were treated with indicated 
concentrations of PLAP, LY311727, and BEL at 25°C for 25 min. Then, PLD enzymatic 
activity was measured as per manufacturer’s instruction at 520 nm/584 nm (Ex/Em) using a 
POLARstar Omega microplate reader. Each condition was measured in triplicate and 
experiments repeated, as indicated (n).  
2.4 Chromaffin cell culture and capacitance measurement 
Adrenal glands were obtained from newborn wild type C57B6N mice. Chromaffin cells were 
harvested from the glands and maintained as primary cultures for three days according to an 
established protocol [65]. Briefly, dissected adrenal glands were placed in Lock’s solution (154 
mM NaCl, 5.6 mM KCl, 5.0 mM HEPES, 3.6 mM NaHCO3, 5.6 mM Glucose) to carefully 
remove connective tissue using a pair of tweezers. Glands were then incubated with enzyme 
solution (20-25 unit/ml papain) in 250 ml Dulbecco's Modified Eagle Medium (DMEM) 
(without sodium and pyruvate) from Thermo scientific (Oregon, USA), with gentle shaking at 
37°C for 25 min. To stop enzyme activity, glands were incubated with inactivation solution 
(225 ml DMEM containing 625 mg trypsin inhibitor, 25 ml heat-inactivated fetal calf serum, 
and 625 mg albumin) for 10 min at 37°C. Subsequently, inactivation solution was carefully 
replaced with fresh DMEM supplemented with 1X penicillin-streptomycin, and Insulin-





30 times) using a micropipette until no piece of tissue was visible. A small volume of cell 
suspension was placed on a sterile coverslip and allowed to adhere at 37°C before overnight 
incubation with ~ 2 ml of fresh DMEM under 8.5 % CO2.   
Borosilicate patch pipettes (GB150F - 8P) were pulled using a Sutter Instrument Model P-87 
(Sutter Instrument, Novato, CA). Pipettes were coated with wax to reduce resistance to <5 Ω. 
During electrical recording, adherent cells on coverslips were immersed in a bath solution (130 
mM NaCl, 4 mM KCl, 10 mM CaCl2, 1mM MgCl2, 10 mM HEPES, 20 mM Glucose); the 
pipette contained patch solution (135 mM CsOH, 135 mM Glutamate, 8mM NaCl, 0.18 mM 
CaCl2, 0.28 mM BAPTA, 10 mM HEPES, 2 mM Mg-ATP, 0.5 mM Na2GTP) without or with 
either 858.0 pM PLAP or 2 nM LY311727. After breaking the Giga seal, chromaffin cells were 
held in the voltage-clamp whole-cell configuration for 2 min to ensure diffusion of PLAP and 
LY311727 into the cytosol before triggering secretion using a train of 200 ms triple 
depolarizing pulses (from -70 mV to +10 mV). Time delays of 0.1 ms and 20 ms were applied 
between pulse -1 and -2 and pulse -2 and -3, respectively [18,19]. The changes in membrane 
capacitance and Ca2+ current (Ica) were recorded using an EPC-7 (HEKA, Lambrecht, 
Germany).  
3. Data Analyses 
In CSC and CV fusion assays, all conditions were tested in quadruplicate and experiments 
repeated as indicated (n). Raw data were normalized by setting zero % fusion at <0.3 µM 
[Ca2+]free and 100 % fusion at >100 µM [Ca2+]free. Ca2+ activity curves were fit using a 
sigmoidal 4-parameter logistic model (PRISM 7.03, GraphPad, San Diego, US). Capacitance 
traces from the indicated number (n) of chromaffin cells were analyzed using Igor software. 






4. Results  
4.1 PLAP blocked late steps in regulated exocytosis 
As with previous studies, endogenously docked CV at the PM (CSC) undergo 
heterotypic fusion upon Ca2+ triggering, yielding a characteristic sigmoidal dose-response 
curve with an EC50 of 33.5 + 8.0 µM [Ca2+]free (Fig. 1B; n=8) [8,12-17,23,24]. Treating CSC 
(OD 0.64 + 0.02; n=3-9) with 2 µM PLAP and 2 µM PLAP + 200 µM LY311727 reduced 
fusion extent to ~60 % and ~40 %, respectively (Fig. 1B; n=5-8); fusion extent reduced to ~13 
% in 200 µM LY311727 treated CSC [9]. Treating CSC with 2 µM PLAP caused no change 
in endogenous FFA. However, when added with 200 µM LY311727, i.e., in 2 µM PLAP + 200 





n=3).We have previously reported a decrease in endogenous FFA by ~ 54 % in 200 µM 
LY311727 treated CSC [9]. No change in fusion extent nor Ca2+ sensitivity occurred in 2 µM 
PLAP + 200µM LY311727 treated CSC, relative to 200 µM LY311727 treated CSC (not 
shown).   
    
4.2 PLAP impaired priming/docking, correlating with changes in endogenous lipids 
To identify whether blockage of the membrane merger or impairment in the 
priming/docking steps reduced fusion extent in the PLAP treated CSC, CV (OD 0.96 + 0.2; 
n=11) were treated with the indicated concentrations of PLAP and LY311727. The treatment 
effects were assessed using the standard (Fig. 2A; n= 3-11) and settle CV-CV fusion assays 
Figure 1: (A) Recombinant melittin (PDB ID 6DST; rainbow ribbon structures) and PLAP are 
73 % identical and 72 % similar, and carry a leucine zipper heptad, characterized by leucine (L) 
separated by six amino acids. Ribbon structures showing interaction between SNARE core 
complex (PDB ID 1GL2; blue structures) and recombinant melittin. Simulation was carried out 
using GRAMM-X Protein-Protein Docking Web Server v.1.2.0 and visualized using UCSF 
Chimera 1.13.1 (B) Effects of PLAP and PLAP + LY311727 on CSC fusion (n=3-9). Changes 
in the Ca2+ activity curves, fusion extent and Ca2+ sensitivity (EC50); (C) Detection and 
quantification of endogenous FFA, n=3 separate experiments in CSC treated with indicated dose 
of PLAP and PLAP + LY311727; a representative chromatogram showing changes in 
endogenous FFA.  (p-value, *< 0.05, **=0.006 indicates relative difference to the control and 
as indicated, ns denotes not-significant) Note: The sections of the chromatogram shown in B 
are grouped together from the same HPTLC plate following removal of lanes not 






(Fig. 2B; n=2-11). In standard assay, only 2 µM PLAP reduced fusion extent to 86.7 + 4.7 % 
(Fig. 2A; n= 11). Also, a significant decrease in Ca2+ sensitivity occurred in 2 µM PLAP + 200 
µM LY311727 treated CV, relative to 2 µM PLAP treated CV (Fig. 2A; n= 3-11). The Ca2+ 
sensitivity reduced to EC 50 of 89.1 + 18.1 [Ca2+]free in 2 µM PLAP + 200 µM LY311727 
treated CV, relative to control EC50 of 44.7 + 4.8 [Ca2+]free (Fig. 2A; n= 4-11).  
 
Importantly, a concentration-dependent decrease in fusion extent to 75.4 + 8.0 %, 63.3 
+ 6.8 % and 57.5 + 13.0 % occurred with 2 µM, 5 µM and 10 µM PLAP, respectively, in the 
settle fusion assay, clearly indicating PLAP impaired priming/docking steps. As above, no 
Figure 2: Effects of increasing doses of PLAP and PLAP + LY311727 on CV-CV calcium 
activity curves, fusion extent and calcium sensitivity (EC50); (A) standard fusion assay, n=3-
11; (B) settle fusion assay, n=2-10. (p-value- *< 0.05, **< 0.0022, ***<0.0002, **** 






change in fusion extent but a significant decrease in Ca2+ sensitivity occurred in 2 µM PLAP 
+ 200 µM LY311727, relative to 2 µM PLAP treated CV in the settle fusion assay (Fig. 2B; 
n= 3-11). The Ca2+ sensitivity was reduced to an EC50 of 132.7 + 14.6 [Ca2+]free in 2 µM PLAP 
+ 200 µM LY311727 treated CV, relative to a control EC50 of 44.1 + 10.3 [Ca2+]free (Fig. 2B; 
n= 3-11). No significant change in Ca2+ sensitivity occurred in 200 µM LY31172 treated CV 
in either assay [9].  
To correlate changes in function with an underlying mechanism, total CV lipids were 
assessed. Treating CV with 10 µM PLAP and 2 µM PLAP + 200 µM LY311727 reduced 
endogenous FFA by ~37 % and ~47 %, respectively (Fig. 3; n=3-15). 
 
Figure 3: Detection and quantification of endogenous FFA, n=3-8 separate experiments in 
CV treated with increasing concentration of PLAP and PLAP + LY311727; representative 
chromatogram showing changes in the total CV neutral lipids. (p-value- *< 0.05, indicates 
relative difference to the control, ns denotes non-significant)  
Note: The sections of the chromatogram shown are grouped together from the same 
HPTLC plate following removal of lanes not associated with this study. A standard 








Endogenous FFA decreased by ~27 % in 200 µM LY311727 treated CV [9]. No change 
in endogenous FFA occurred in CV treated with 2 µM PLAP + 200 µM LY311727, relative to 
2 µM PLAP (Fig. 3; n=3-15). Beside altering endogenous FFA, treating CV with PLAP also 
caused a concentration-dependent increase in endogenous PE (Fig. 4; n=3-17). The 
endogenous PE significantly increased to 68.5 + 8.7 pmoles / µg MP in 10 µM PLAP treated 
CV, relative to 47.0 + 4.0 pmoles / µg MP in control (Fig. 4; n=3-17). No changes in any other 
lipids were observed (see chromatograms shown in Figs. 3 and 4). 
4.3 Cumulative effects of PLAP and PLA2 inhibitors modulated Ca2+ sensitivity  
Our previous study established that treating CV with BEL and FKGK-11, selective iPLA2 
inhibitors, significantly reduced fusion in both the standard and settle fusion assays [9]. 
Supplementing BEL with PLAP (i.e., 500 µM BEL + 2 µM PLAP) also reduced fusion extent 
Figure 4: Detection and quantification of endogenous PE in CV treated with increasing 
concentration of PLAP (n=3-17), and representative chromatogram showing changes in the 
total CV phospholipids. (p-value- *< 0.05, indicates relative difference to the control)  
Note: The sections of the chromatogram shown are grouped together from the same 
HPTLC plate following removal of lanes not associated with this study. A standard 



















to 81.3 + 9.5 % in the standard fusion assay (Fig. 5A; n=6-7) and to 80.1 + 4.1 % in the settle 
fusion assay (Fig. 5B; n=3-4). Similarly, supplementing FKGK-11 with PLAP reduced fusion 
extent to 86.0 + 3.5 % in the standard assay (Fig. 5A; n=6-7) and to 78.0 % + 9.6 in the settle 
fusion assay (Fig.5B; n=3-4). Notably, treating CV with 500 µM BEL + 2 µM PLAP and 200 
µM FKGK-11 + 2 µM PLAP, significantly reduced Ca2+ sensitivity to an EC50 of 110.9 + 16.9 
µM [Ca2+]free and 74.8 + 8.0 µM [Ca2+]free respectively, relative to the control EC50 of 50.3 + 




Figure 5: Effects of PLAP + BEL and PLAP + FKGK-11 on CV-CV calcium activity curves, 
fusion extent and calcium sensitivity (EC50); (A) standard fusion assay, n=6-7; (B) settle 
fusion assay, n=3-4. (p-value, *< 0.05, **<0.005, ***=0.0001 indicate relative difference to 










As above, to correlate functional changes with the molecular targets, lipid analyses 
were carried out. Treating CV with 500 µM BEL and 200 µM FKGK-11 reduced endogenous 
FFA by ~ 92 % and 18 %, respectively [9]. Supplementing 2 µM PLAP with inhibitors, i.e., 
treating CV with 2 µM PLAP + 500 µM BEL and 2 µM PLAP + 200 µM FKGK-11, reduced 
endogenous FFA below background and by ~14 %, respectively (Fig. 6; n=3-4). No change 
occurred in endogenous FFA levels in CV treated with 500 µM BEL + 2 µM PLAP, relative 
to 500 µM BEL treated CV and in 2 µM PLAP + 200 µM FKGK-11 treated CV, relative to 
200 µM FKGK-11 treated CV. This indicates that PLAP did not alter CV membrane-associated 
iPLA2 activity (not shown, part of the data is published in [9]).  
 
 
Additionally, to investigate whether PLAP modulated PLD activity, the enzymatic activity was 
measured in CV (OD 0.83 + 0.01; n=3-4) following treatment with the indicated doses of 
Figure 6: Changes in the endogenous FFA (n=3-4) in CV treated with indicated doses of BEL + 
PLAP and FKGK-11 + PLAP; representative chromatograms showing changes in total CV 
neutral lipids. (p-value, *< 0.05 indicates relative difference to the control and as indicated).  
Note: The sections of the chromatogram shown are grouped together from the same 
HPTLC plate following removal of lanes not associated with this study. A standard neutral 









PLAP, LY311727 and BEL. The estimated PLD activity in an untreated control was 66.7 U/ml 
which is consistent with our previous study [16]. No change in basal PLD activity occurred in 
CV treated with the indicated concentrations of PLAP, LY311727, and BEL and also when 
PLAP was supplemented with LY311727 and BEL (Table-1; n=3-4).  
 
 
4.4 PLAP inhibits regulated secretion by impairing mechanisms that reduced RRP size.  
Depolarization of chromaffin cells that were internally dialyzed with 860.0 pM PLAP 
or 2 nM LY311727, resulted in a significant decrease in exocytosis as indicated by reduced 
changes in membrane capacitance (Fig. 7A; n=4-9); ΔCm1, ΔCm2, and ΔCm3 represent change in 
membrane capacitance triggered by depolarizing pulses -1, -2 and -3, respectively. The 
 PLD 
U/ml 
SEM sample size (n) Student’s t-   test 
Control 66.7 4.4 4  
2 µM PLAP 63.3 3.3 4 0.60 
20 µM LY311727 55.8 2.6 4 0.15 
200 µM LY311727 33.4 11.9 3 0.06 
200 µM LY311727 + 2 µM PLAP 33.9 12.1 3 0.07 
100 µM BEL 57.4 5.7 3 0.29 
500 µM BEL 53.2 6.3 4 0.17 
500 µM BEL +  2 µM PLAP 51.1 6.4 4 0.12 
Table -1: No significant change in CV associated PLD activity following treatment with the 

















significant decrease in ΔCm2 to 23.8 + 3.8 fF/pF occurred in cells treated with 860.0 pM PLAP, 
relative to control ΔCm2 of 46.9 + 5.3 fF/pF (Fig. 7A; n=7-9). No change in ΔCm1 and ΔCm3 
was observed with 860.0 pM PLAP. Notably, ΔCRRP also reduced to 127.2 + 21.0 fF in 860.0 
pM PLAP treated cells, relative to 272.5 + 37.8 fF observed in the controls (Fig. 7B; n=7-9). 
Similarly, LY311727 significantly reduced ΔCm1 and ΔCm3 to 17.12 + 12.6 fF/pF and 16.5 + 
4.5 fF/pF, respectively (Fig. 7A; n=4-9) and also caused a significant decrease in ΔCRRP to 36.0 








Figure 7: Effect of 860.0 pM PLAP and 2 nM LY311727 on membrane capacitance and RRP 
size in mouse chromaffin cells (n=4-9). (A) Changes in membrane capacitances (denoted as 
ΔCm1, ΔCm2 and ΔCm3) in response to triggering with a train of three depolarizing pulses and; 
(B) Changes in the size of the release-ready pool (denoted as ΔCRRP). Representative trace 
showing changes in the capacitance measurement in cells treated with PLAP (black) and 
LY311727 (blue). (p value, * < 0.05, ** < 0.007 indicate relative difference to the control and 





5. Discussion  
Here, using native CSC and CV, we show for the first time that PLAP reduced fusion of 
endogenously docked CV with the PM (i.e., exocytosis in vitro) (Fig. 1B; n=3-9) and a more 
profound decrease in fusion extent in the settle fusion assay, relative to the standard assay (Fig. 
2A, B). This confirmed that PLAP impaired molecular reactions associated with 
priming/docking. The decrease in function correlated with reduced endogenous FFA (Fig. 3) 
and increased endogenous PE (Fig. 4) in the PLAP treated CV. Additionally, PLAP reduced 
Ca2+ sensitivity, when supplemented with LY311727, BEL, and FKGK-11 (Fig. 2A, B and; 
Fig. 5B) but caused no change in the CV associated PLD (Table-1) and iPLA2 activities. The 
more profound decrease in fusion extent in the settle fusion assay is consistent with a significant 
decrease in overall secretion and reduced RRP size in PLAP treated chromaffin cells. Overall, 
the data indicate that PLAP blocked common underlying molecular reactions associated with 
the late steps of regulated exocytosis in both of these secretory cell types.  
5.1 PLAP altered lipid homeostasis in native membranes and impaired priming/docking 
PLAP contains a dimerization motif, and thus can potentially form homo or 
heterodimers, also with the SNARE complexes (Fig. 1A). Such interactions might also block 
trans SNARE complex formation and NH2 terminus-to-COOH terminus SNARE ‘zippering’ 
due to steric hindrance, (also see Discussion, page 65). Treating CSC with 2 µM PLAP caused 
no significant change in any endogenous lipids, relative to the control. However, a profound 
decrease in fusion extent to ~61 % was observed (Fig. 1B; n=3). We had anticipated an increase 
in endogenous FFA, relative to the control due to the suggested stimulatory action of PLAP on 
CV luminal sPLA2 [1,4,61]. Hence, to confirm that luminal sPLA2 was active in the 
preparation, a potent compound, LY311727 was added with 2 µM PLAP (i.e., treating CSC 





to CSC treated only with PLAP but nevertheless caused no additional change in the fusion 
extent nor Ca2+ sensitivity (Fig. 1B).  Importantly, as CV did not burst in PLAP treatments, 
which would be indicated by a drastic decrease in absorbance, this indicated that CV luminal 
sPLA2 was inaccessible. This suggested that PLAP monomers interacted with pre-formed 
native molecular interactions between CV and PM, possibly including already formed and 
zippered trans SNARE complexes. This would cause steric hindrance to the SNARE action of 
maintaining priming/docking.  
In CSC treatments, PLAP might also have altered those PM (proteins or lipids) 
constituents that do not play direct roles in the late stages of regulated exocytosis, thus causing 
‘background’ effects. Therefore, it was essential to understand the action of PLAP using 
isolated CV. Treating isolated CV with 2 µM, 5 µM and 10 µM PLAP reduced fusion extent 
by ~25%, ~36%, and ~42%, respectively in the settle fusion assay (Fig. 2B) and; 2 µM PLAP 
also reduced fusion extent by ~13 % % in the standard fusion assay (Fig. 2A). However, the 
decrease in fusion extent in 2 µM PLAP treated CV was the same in both the standard and 
settle fusion assays. Therefore, 2 µM PLAP actually reduced priming/docking steps (as 
measured by the settle fusion assay) as these precede the actual membrane merger steps 
(measured by the standard fusion assay). This observation is also confirmed by a concentration-
dependent decrease in fusion extent in the settle fusion assay. Overall, it appears that PLAP 
interacted with CV surface proteins, to impair priming/docking steps (Fig. 2), reduce 
endogenous FFA (Fig. 3) and increase endogenous PE (Fig. 4).  
5.2 Ca2+ sensing and priming/docking steps are inter-linked.  
Treating CSC with 2 µM PLAP + 200 µM LY311727 did not reduce Ca2+ sensitivity 
nor fusion extent, relative to the 2 µM PLAP treated CSC (Fig. 1B). However, treating CV 
with 2 µM PLAP + 200 µM LY311727 significantly reduced Ca2+ sensitivity by ~ 50% and ~ 





(Fig. 2). Such a pattern of reduced Ca2+ sensitivity also occurred in 500 µM BEL + 2 µM PLAP 
treated CV and by >100 % in 200 µM FKGK-11 + 2 µM PLAP treated CV in the settle fusion 
assay (Fig. 5). These data indicated that during isolation of CV from the PM (using lower pH 
and a chaotropic buffer [22,50]), the pre-formed molecular interactions that maintain 
priming/docking and Ca2+ sensitivity uncouple. Nonetheless, after isolation, such interactions 
(although inter-vesicular) again form under the conditions of both the standard and settle CV-
CV fusion assays, to re-establish priming/docking. PLAP reduced Ca2+ sensitivity when 
supplemented with LY311727, BEL, and FKGK-11 in the CV-CV fusion assays (Figs. 2 and 
5) but caused no change in Ca2+ sensitivity nor fusion extent in the CSC fusion assays (Fig. 
1B). This indicates that cumulative effects of PLAP and inhibitors blocked priming/docking 
and Ca2+ sensing only when new molecular interactions were required to re-establish 
priming/docking between contacting CV. No such effects of reduced priming/docking or Ca2+ 
sensitivity occurred when native interactions already existed between endogenously docked 
CV at the PM. This indicated that molecular reactions relating to Ca2+ sensing and 
priming/docking are closely related as a more profound decrease in Ca2+ sensitivity was 
observed in the priming/docking assay, relative to standard fusion assay.  
5.3 PLAP caused no change in other CV associated enzymes activities 
PLAP is suggested to stimulate sPLA2 in vitro [1, 4,61]. In contrast, a concentration-
dependent decrease in endogenous FFA in PLAP treated CV (Fig. 3) indicated a decrease in 
CV associated PLA2 activities [9,10]. Importantly, PLAP did not form membrane pores which 
would have resulted in bursting and thus loss of intact CV. Instead, the concentration-
dependent decrease in fusion extent with PLAP treatments indicated blockade in the loss of 
intact CV that occurs due to CV-CV or CV-PM fusion (Fig. 2). Hence, CV luminal sPLA2 also 
remained inaccessible to PLAP. This was further confirmed in that there was no change in 





treated CV (Fig. 3). We have previously shown that 500 µM BEL and 200 µM FKGK-11 
inhibit CV membrane-associated iPLA2 [9]. Therefore, to investigate whether PLAP reduced 
FFA by decreasing CV surface iPLA2 activity, separate aliquots were treated with 2 µM PLAP 
+ 500 µM BEL and 2 µM PLAP + 200 µM FKGK-11 and endogenous FFA measured (Fig. 6). 
No significant decrease in fusion extent nor endogenous FFA was observed in 500 µM BEL + 
2 µM PLAP treated CV, relative to 500 µM BEL treated CV. Similarly, fusion extent and 
endogenous FFA remain unchanged in 200 µM FKGK-11 + 2 µM PLAP treated CV, relative 
to 200 µM FKGK-11 treated CV (not shown, part of the data is published in [9]). These 
observations confirm that PLAP did not modulate CV associated iPLA2 activity. Unaltered 
TAG levels in PLAP treated CV (see chromatograms shown in Fig. 3), unlike BEL treatments 
that shifted the lipid homeostasis toward the de novo cycle due to blockade of the iPLA2 activity 
[9,71], was also consistent with these observations. Additionally, no change in PLD activity in 
CV treated with the indicated doses of PLAP, LY311727 and BEL (Table 1) indicated that 
PLD possibly acts upstream of PLA2 isozymes in the biochemical pathways underlying the late 
steps of regulated exocytosis [9,16].  
5.4 PLAP blocks regulated exocytosis and reduce RRP size in mammalian cell 
Recently, Narayana et al. showed that isolated secretory vesicles maintain basal levels of 
saturated as well as unsaturated FFA species in the range of 0.0025µM - 5µM per 100 µg of 
secretory vesicles [72]. These levels also increased significantly following 100 mM Ca2+ 
treatment [72]. This Ca2+ dose is of course highly non-physiological and hence worth noting. 
On checking other references, that are also included in [72], it seems that authors may have 
mistakenly mentioned 100 mM Ca2+ instead of 100 µM Ca2+ although there is no indication of 
whether these are meant to indicate total or [Ca2+]free values. We also note that there are no 
updated versions of [72], correcting the same. As ARA and DHA are mainly esterified at the 





94 %), after exposing secretory vesicles to 100 mM Ca2+ indicated that the vesicles carry a 
calcium-dependent PLA2 isozyme(s). These observations are consistent with the basal 
endogenous FFA levels of ~15 fmoles / µg CV MP in isolated CV and identification of Ca2+-
dependent CV luminal sPLA2 [9].  
Therefore, to investigate, whether PLAP and LY311727 [9] could also reduce regulated 
exocytosis in another secretory cell type, both these compounds were internally dialyzed into 
chromaffin cells via patch pipettes. The cells that were delivered 858.0 pM PLAP had a ΔCm2 
that was reduced by ~49 % (Fig. 7A). In contrast, cells that were delivered 2 nM LY311727 
had a ΔCm1 that was reduced by ~88 % and ΔCm3 by ~70 % (Fig. 7A). Thus, both test 
compounds reduced regulated secretion. Importantly, both 858.0 PLAP and 2 nM LY311727 
also reduced the RRP by ~53 % and ~87 %, respectively (Fig. 7A). Using a capacitance value 
of 1.3 fF per vesicle [20], the estimated number of the secretory vesicle in the RRP under 
control conditions was ~212, consistent with previous studies [20,51]. This number was 
significantly reduced to ~98 and ~28 in cells treated with 858.0 pM PLAP and 2 nM LY311727, 
respectively. The decrease in RRP size can also occur due to inhibition in the refilling of 
vesicles from downstream (SRP) pool, in addition to impaired priming/docking. Notably, 
recovery of secretory vesicles into the RRP typically occurs in seconds after triggering their 
release using depolarizing pulse [73,74]. This indicates that due to the <20 ms delay that was 
applied between depolarizing pulses, any such impairment in the refilling process had no effect 
in reducing RRP size [75]. This would be consistent with reduced vesicle numbers in the RRP 
following treatment with PLAP or LY311727 occurring due to an impaired molecular state of 








Overall, using well-established model systems, CSC and CV-CV fusion assays – that enable 
tight coupling of the functional and molecular analyses [8,11-17] - and membrane capacitance 
measurements of size in chromaffin cells [18-20,73], the data here confirm that PLAP impaired 
common underlying mechanisms that disturbed endogenous lipid levels and impaired 
priming/docking steps. Also, PLAP did not form membrane pores nor modulate CV luminal 
sPLA2 and PLD activities, contrary to earlier studies. Furthermore, critical interactions between 
Ca2+ sensors and components associated with priming/docking are also indicated.  
Abbreviations: CV - cortical vesicles; CSC - cell surface complexes; ΔCm - change in 
capacitance; ΔCRRP - change in RRP size; [Ca2+]fee - free calcium concentration; FFA - free 
fatty acid; PLAP - phospholipase A2 activating peptide; RRP – readily releasable pool 
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CHAPTER – 5 
 
























General Discussion and Future Directions 
The late steps of Ca2+ triggered exocytosis involve Ca2+ sensing, docking, priming, and 
membrane merger. Hence, to understand steps preceding membrane merger, one must consider 
the basal biochemical state of the system (i.e., unstimulated), and this is true for all potentially 
active molecular species, including membrane lipids. My working hypothesis states that 
localized PLA2 supply FFA (e.g., ARA) and LPL (e.g., LPC) near docking / fusion sites; LPC 
in the proximal monolayers acts as a molecular fusion ‘brake’ to block spontaneous membrane 
merger while ARA aids in SNARE mediated priming/docking [1]. The data presented in 
Chapter 2 indicate that catalytically active endogenous vesicle-associated PLA2 isoforms –  
iPLA2 on the CV surface and sPLA2 in the CV lumen – carry out these orchestered roles in 
regulating and maintaining vesicle priming/docking [2]. This resolves a long-standing question 
in the field as to the possible role(s) of PLA2 in exocytosis [3-6]. As proteolytic cleavage of 
CV surface proteins (including SNAREs and iPLA2) significantly reduced priming/docking, 
this suggested a need to investigate whether SNARE mediated priming/docking requires 
functional iPLA2 [2]. However, due to time constraints, direct assays of SNARE interactions 
could not be carried out. To further probe the role(s) of PLA2, the data presented in Chapter 3 
show that addition of the canonical PLA2 metabolites ARA and LPC, respectively, inhibit 
priming/docking and the membrane merger step of regulated exocytosis. That exogenous LPC 
blocked membrane merger (likely at an initiating step [7-11]) is consistent with the working 
hypothesis [1] and identification of iPLA2 on the CV surface, that can generate local LPC to 
block spontaneous membrane merger [2]. However, that exogenous ARA impaired 
priming/docking is contradictory of the suggested supporting role of PLA2 generated ARA in 
promoting SNARE complex formation [1]. This portion of the working hypothesis was 
proposed based on earlier in vitro [12-14] and in vivo [15,16] studies suggesting that ARA 
promoted SNARE complex formation and interacted with SNARE microdomains. However, a 
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crucial consideration relating to ARA supplementation in whole-cell studies is its rapid 
metabolism to generate shorter FFA species [17,18], that then reorganize FFA species in the 
membrane phospholipids [18-20]. Indeed, the data presented in Chapter 3, show that even 
isolated CV carry native enzymes to convert exogenous ARA into endogenous FFA within 10 
min; nevertheless, using a non-metabolizable analogue, it was also clear that exogenous ARA 
directly impaired the priming/docking steps of regulated exocytosis [11]. Does this imply that 
ARA altered membrane biophysical properties by reorganizing FFA species in membrane 
phospholipids that reduced priming/docking? Importantly, priming and docking steps are 
considered as the functional consequence of SNARE complex formation and ‘zippering’ [2,21-
26]. If so, then the ARA induced decrease in priming/docking, and studies suggesting ARA 
promotes SNARE complex formation are inconsistent. Hence, the claim of ARA promoted 
SNARE complex formation thus requires more focussed investigation. In this regard, probing 
changes in individual native SNARE monomers and complex formation in ARA treated CV, 
relative to control would likely prove useful.   
Additionally, data presented in Chapter 4 showed that PLAP, a melittin homolog, 
inhibited CSC and CV fusion by impairing priming/docking but caused no change in the CV 
luminal sPLA2 activity. Melittin is a polypeptide that tends to form α-helical monomers. It can 
also oligomerize to form dimers or tetramers [27,28], likely via a leucine zipper dimerization 
motif. Nevertheless, under physiological conditions and a low peptide-to-lipid ratio, melittin 
exists as a monomer [28]. According to the proposed mechanism of Terwilliger et al., at low 
concentrations, melittin monomers orient parallel to the outer monolayer, thus increasing the 
surface area of the outer monolayer [29,30]. This eventually results in the formation of 
membrane pores when melittin concentrations exceed a critical peptide-to-lipid ratio due to the 
imbalance in the surface area of the outer monolayer relative to the inner monolayer [29,30]. 
As PLAP shares high identity and similarity with melittin, including a leucine zipper motif, it 
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is also expected to form membrane pores, as described above. However, in contrast, PLAP 
blocked fusion by impairing priming/docking steps. As PLAP did not form membrane pores 
(which would have resulted in bursting and thus loss of intact CV), CV luminal sPLA2 remained 
inaccessible, and therefore its activity was unaltered by PLAP; the recognized stimulatory 
action of PLAP has only been demonstrated on already released sPLA2 [31,32]. This thus 
indicates that PLAP concentration in the CSC and CV treatments was likely below the critical 
peptide-to-lipid ratio. Due to this, it would appear that PLAP monomers likely interacted with 
the molecular entities on the outer CV monolayer, thus blocking inter-membrane contact and/or 
trans SNARE complex formation and ‘zippering’ due to steric hindrance. Importantly, PLAP 
impaired priming/docking steps and also altered endogenous PE and FFA levels, indicating 
that priming/docking, the endogenous lipid composition, and SNARE complex formation or 
‘zippering’ could be inter-related. These are interesting observations that warrant more 
focussed future studies. 
Overall, the findings in Chapters 2 and 3 are novel and significant as they further contribute 
to our understanding of how PLA2 and its metabolites contribute to the fundamental molecular 
mechanisms that modulate the late steps of regulated exocytosis. Additionally, data presented 
in Chapter 4 further highlight the similarity in the molecular state of RRP secretory vesicles 
in the chromaffin cell and fully primed release-ready CV. 
The concentration of non-bilayer forming lipids (e.g., LPC, Cholesterol, ARA), relative 
to bilayer forming lipids (e.g., PC) in the membrane modulates the progression of membrane 
merger steps after initial membrane contact [1,8,10,33]. In this regard, all membrane-bound 
enzymes and those present in the vesicle lumen that can cleave bilayer forming phospholipids 
to generate non-bilayer forming lipids are critical. These include phospholipases A1 (PLA1), 
phospholipase B (PLB) and phospholipase C (PLC). PLB and PLC cleave membrane 
phospholipids to generate LPL and FFA, and DAG and inositol triphosphate (IP3), respectively. 
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Importantly, isolated secretory vesicles also generate saturated FFA in an unstimulated state, 
possibly due to the basal activity of vesicle-associated PLA1 [34]. Therefore, to identify their 
roles in the late steps of regulated exocytosis, inhibiting PLA1 isozyme activities using 
diisopropylfluorophosphate and arachidonyl fluorophosphonate [35] and studying treatment 
effects using functional assays [2,36,37] would be informative.  
Importantly, the data presented in Chapters 2 and 3 indicate that a dynamic equilibrium 
among lipid species in the native CV membrane is under tight regulation by the action of 
endogenous enzymes [2,36,37]. Therefore, outcomes of lipid supplementation should be 
carefully considered as added lipids also disturb the equilibrium between the lipid species in 
the biochemical pathways, thus complicating interpretation of the data. Importantly, for some 
enzymes, Ca2+ could be an essential co-factor [38,39], so that these might also be considered 
to act as Ca2+ sensors operating at low [Ca2+]free to regulate docking and priming, as has also 
been suggested [26,40]. Therefore, identification and characterization of such CV associated 
Ca2+-binding enzymes can be done using Immobilized Metal Chelate Affinity Chromatography 
(IMAC) [41,42] and top-down proteomics [2,42,43]. The Ca2+ sensing ability of these enzymes 
can then be confirmed by modulating their activities, as was previously done [2,36,44,45] to 
study the associated effects in the standard and settle fusion assays [2,22,37,44,46-48]. After 
identification, characterization, and purification, such membrane attached enzymes that act as 
Ca2+ sensors can also be reconstituted with correct orientation in (PC/PE/PS/PI/cholesterol) 
giant unilamellar liposomes (GUV) [49] to confirm their role via heterotypic CV-GUV fusion 
[50]. The orientation of reconstituted proteins in the membrane can be confirmed using trypsin 
[49], western blotting, and enzyme assays. This approach would also be useful in quantifying 
the minimum copy number of the target protein required to carry out its role in the GUV-CV 
fusion assay.  
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As iPLA2 has been identified on the outer CV monolayer, it would also be interesting 
to investigate whether Botulinum toxin types B/C/F (BoNT B/C/F) could modulate its activity, 
in addition to the cleavage of SNAREs [51].  If so, what effects does this then exert on the 
priming/docking steps and how to dissociate the effects of toxin treatments on SNAREs vs. 
iPLA2? The BoNT B and F toxins cleave VAMP 2 at peptide bonds after Q78 and L56, 
respectively and BoNT C cleaves both SNAP 25 and syntaxin at peptide bonds after R198 and 
K252 [51]. Therefore, carrying out residue-specific reversible modifications or ‘bioconjugation’ 
[52] to block BoNT B/C/F cleavage sites on CV SNAREs coupled with standard and settle 
fusion assays [2,36,37,45,47] would be useful to dissociate the effects of SNAREs and iPLA2 
on priming/docking. This would first involve blocking of BoNT B/C/F cleavage sites on the 
CV SNAREs by modifying their Q, L, and R residues [52], thus allowing toxin-induced 
modification in the iPLA2 activity during treatments. With this, the selective effects of toxins 
on iPLA2, and therefore on priming/docking would be confirmed. In the next step, treating CV 
aliquots (that carry modified Q, L, R residues) with toxins but after unblocking BoNT B/C/F 
cleavage sites on CV SNAREs [52] would now allow cleavage of the SNAREs during 
treatments. Effects on the functional assays would now reflect the roles of SNAREs in 
priming/docking. Nevertheless, while this study looks promising, initial experiments to 
optimize conditions for efficient and selective amino acid modifications, and to probe any 
associated ‘background’ effects of bioconjugation would be essential. 
Furthermore, CV luminal [Ca2+]free transients occur in the range of ~1-10 µM due to 
opening/closing of p-type Ca2+ channels [53]. Therefore local [Ca2+]free at the inner CV 
membrane would likely be higher than the global average in the CV lumen itself [2]. Therefore, 
to confirm that during Ca2+ transients localized Ca2+-dependent CV luminal sPLA2 activity at 
the inner CV membrane also increases [2], monitoring changes in the PED6 labelled inner 
monolayer of an intact CV together with luminal [Ca2+]free levels using Indo-1 might be 
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promising. PED 6 is a selective PLA2 substrate that has absorption and emission maxima at 
~488 nm and ~530 nm, respectively [2]. However, as CV also carry an active surface iPLA2, 
it would thus be essential to inhibit its activity before PED6 labeling using a selective inhibitor, 
such as Bromoenol lactone (BEL) [2]. Indo-1 is a high Ca2+ affinity ratiometric dye that has an 
absorption maximum at ~350 nm, and two emission maxima at ~405 nm and ~485 nm, 
corresponding to the bound and unbound [Ca2+] states, respectively [54]. Given that emission 
maxima of PED6 and Indo-1 are well-separated (530 nm vs. 405nm), a single (argon) laser 
would be able to generate well-separated emission spectra from both fluorophores; argon lasers 
emit 13 wavelengths, including 488nm and 351nm. Using select filters and detectors on the 
microscope, these spectra would thus produce separate corresponding images, and when 
superimposed would show co-related spatiotemporal changes in localized sPLA2 activity and 
[Ca2+]free levels [53,55]. Nevertheless, the biggest technological challenge relating to this study 
will be the acquisition of super-resolution fluorescent images of isolated CV that have an 
average diameter of ~1 µM [53,56]. Further, interference due to potential auto-fluorescence 
from the biological samples upon excitation at 350 nm might also pose an issue.   
The molecular definition and distinction between priming/docking are still unknown 
[57,58]; nevertheless, it has been long known that at least some priming reactions require ATP 
[59,60], perhaps to phosphorylate SNAP 25 [61,62], synaptotagmin [63], and 
phosphatidylinositol to generate Phosphatidylinositol 4,5-bisphosphate (PIP2) [64-66]. The 
settle fusion assay evaluates the priming/docking capacity of CV by allowing them to freely 
undergo the biochemical reactions that support inter-membrane attachment. Therefore, 
molecular targets of the phosphorylation reactions associated with priming/docking, can be 
measured by assessing changes in ATP [67-69] and total CV lipids (including PIP2) using top-
down lipidomics at the beginning (0 hr), mid-point (30 min) and end of the incubation (1 hr) 
and co-relating these changes with the outcome of the functional assays carried out at the end 
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of each incubation. This test can further be extended to assess changes in CV luminal and 
membrane proteins using top-down proteomics at the end of each incubation to identify protein 
targets of the phosphorylation reaction. 
In conclusion, homotypic CV fusion, as well as heterotypic CV-PM fusion, are 
excellent stage-specific models which can still teach us a great deal concerning the late steps 
of regulated exocytosis, including Ca2+ sensing, docking, priming, and membrane merger. 
Using biochemical and molecular assays, targeted omics coupled with functional analyses and 
single-vesicle super-resolution microscopy, unidentified molecular targets (protein, lipid or 
both) associated with the above mentioned steps can be identified to further co-relate their 
biochemical state (e.g., levels of phosphorylation) with priming/docking.  
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